<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Biosaf Health</journal-id><journal-id journal-id-type="iso-abbrev">Biosaf Health</journal-id><journal-id journal-id-type="pmc-domain-id">4710</journal-id><journal-id journal-id-type="pmc-domain">biosafhealth</journal-id><journal-title-group><journal-title>Biosafety and Health</journal-title></journal-title-group><issn pub-type="ppub">2096-6962</issn><issn pub-type="epub">2590-0536</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11894984</article-id><article-id pub-id-type="pmcid-ver">PMC11894984.1</article-id><article-id pub-id-type="pmcaid">11894984</article-id><article-id pub-id-type="pmcaiid">11894984</article-id><article-id pub-id-type="pmid">40078604</article-id><article-id pub-id-type="doi">10.1016/j.bsheal.2022.11.002</article-id><article-id pub-id-type="pii">S2590-0536(22)00175-6</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Immunologically effective biomaterials-enhanced vaccines against infection of pathogenic microorganisms</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name name-style="western"><surname>Wei</surname><given-names initials="Q">Qi</given-names></name><xref rid="af005" ref-type="aff">a</xref><xref rid="af010" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au010"><name name-style="western"><surname>Liu</surname><given-names initials="S">Shixian</given-names></name><xref rid="af005" ref-type="aff">a</xref><xref rid="af015" ref-type="aff">c</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au015"><name name-style="western"><surname>Huang</surname><given-names initials="X">Xu</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au020"><name name-style="western"><surname>Xin</surname><given-names initials="H">Hua</given-names></name><xref rid="af010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au025"><name name-style="western"><surname>Ding</surname><given-names initials="J">Jianxun</given-names></name><email>jxding@ciac.ac.cn</email><xref rid="af005" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><aff id="af005"><label>a</label>Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun 130022, China</aff><aff id="af010"><label>b</label>Department of Thoracic Surgery, China-Japan Union Hospital of Jilin University, 126 Xiantai Street, Changchun 130033, China</aff><aff id="af015"><label>c</label>Department of Orthopedics, The Second Hospital of Jilin University, 218 Ziqiang Street, Changchun 130041, China</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author: Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun 130022, China. <email>jxding@ciac.ac.cn</email></corresp><fn id="fn1"><label>1</label><p id="np005">These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><month>2</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>02</day><month>12</month><year>2022</year></pub-date><volume>5</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">483915</issue-id><fpage>45</fpage><lpage>61</lpage><history><date date-type="received"><day>18</day><month>5</month><year>2022</year></date><date date-type="rev-recd"><day>27</day><month>11</month><year>2022</year></date><date date-type="accepted"><day>27</day><month>11</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>12</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>12</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-13 09:26:13.310"><day>13</day><month>03</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2022 Chinese Medical Association Publishing House. Published by Elsevier BV.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Chinese Medical Association Publishing House. Published by Elsevier BV.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract abstract-type="author-highlights" id="ab005"><title>Highlights</title><p><list list-type="simple" id="l0005"><list-item id="o0005"><label>&#8226;</label><p id="p0005">Immunologically effective biomaterials are advanced vaccine delivery systems of the spatiotemporally controlled release of antigens.</p></list-item><list-item id="o0010"><label>&#8226;</label><p id="p0010">Immunologically effective biomaterials are promising vaccine adjuvants to enhance the immunogenicity of vaccines.</p></list-item><list-item id="o0015"><label>&#8226;</label><p id="p0015">Biomaterials-enhanced vaccines induce cross-protective immunity against different mutant strains of pathogenic microorganisms.</p></list-item><list-item id="o0020"><label>&#8226;</label><p id="p0020">Biomaterials-enhanced vaccines activate long-lasting and memory immune responses to neutralize or clear pathogenic microorganisms.</p></list-item></list></p></abstract><abstract id="ab010"><p>Infectious diseases are severe public health events that threaten global health. Prophylactic vaccines have been considered as the most effective strategy to train the immune system to recognize and clear pathogenic infections. However, the existing vaccines against infectious diseases have several limitations, such as difficulties in mass manufacturing and storage, weak immunogenicity, and low efficiency of available adjuvants. Biomaterials, especially functional polymers, are expected to break through these bottlenecks based on the advantages of biocompatibility,&#160;degradability, controlled synthesis, easy modification, precise targeting, and immune modulation, which are excellent carriers and adjuvants of vaccines. This review mainly summarizes the application of immunologically effective polymers-enhanced vaccines against viruses- and bacteria-related infectious diseases and predicted their potential improvements.</p></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>Immunologically effective biomaterial</kwd><kwd>Polymer</kwd><kwd>Adjuvant</kwd><kwd>Vaccine</kwd><kwd>Pathogenic microorganism infection</kwd><kwd>Prevention and treatment</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0025">Infectious diseases are one of the leading causes of global health threats. One of the most iconic epidemics is the worldwide outbreak of coronavirus disease 2019 (COVID-19). As of 2022, more than 640 million people have already been infected with COVID-19, and more than 6.6 million have died <xref rid="b0005" ref-type="bibr">[1]</xref>. In addition, the 2009 H1N1 swine influenza pandemic, the acquired immunodeficiency syndrome (AIDS) epidemic caused by the human immunodeficiency virus (HIV) in the 1980s, as well as viral hepatitis, which has not been eradicated for thousands of years, have caused enormous economic losses and social unrest <xref rid="b0010" ref-type="bibr">[2]</xref>, <xref rid="b0015" ref-type="bibr">[3]</xref>, <xref rid="b0020" ref-type="bibr">[4]</xref>. While viral infection causes most infectious diseases, some bacterial infection also causes significant risks. Examples include <italic toggle="yes">Streptococcus pneumoniae (S. pneumoniae)</italic> or <italic toggle="yes">Mycobacterium avium</italic>, which cause the spread of pneumonia or tuberculosis (TB) <xref rid="b0025" ref-type="bibr">[5]</xref>, <xref rid="b0030" ref-type="bibr">[6]</xref>. In addition, pathogenic <italic toggle="yes">Escherichia coli</italic> (<italic toggle="yes">E. coli</italic>) in the digestive tract is also reported to be one of the top five causes of diarrhea and death in children in developing countries <xref rid="b0035" ref-type="bibr">[7]</xref>. Therefore, preventing infectious diseases caused by these pathogens is a top priority for the health sectors. However, there are currently limited effective drugs to prevent virus infection. For instance, although several antiviral medications are used to avoid HIV infection, their use is limited due to drug resistance, cost, and other constraints. In addition, antimicrobial drugs also face a great challenge of spawning super-resistant bacteria <xref rid="b0040" ref-type="bibr">[8]</xref>.</p><p id="p0030">Vaccination is of great value in preventing pathogenic infection, as it has significantly reduced the incidence of major epidemics, such as measles, and even resulted in the eradication of smallpox, according to the report of World Health Organization (WHO) <xref rid="b0045" ref-type="bibr">[9]</xref>. Vaccination activates antigen-presenting cells (APCs) by presenting antigens and/or providing immune adjuvants to activate humoral and cellular immunity. The humoral immune system includes B cells and antibodies, while the cellular immune system comprises T cells. Upon recognizing the antigens, B cells are activated and secrete neutralizing antibodies, and T cells secret cytokines and directly kill the infected cells to train the body's protective immune responses to recognize and fight against invasion and infection by pathogenic microorganisms <xref rid="b0050" ref-type="bibr">[10]</xref>. The existing vaccines, such as live attenuated, inactivated, subunit/peptide, and nucleic acid vaccines, work on this principle, but each type meets some problems <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>. Live attenuated or inactivated vaccines have safety concerns, while subunit vaccines improve safety but are less immunogenic. Cutting-edge nucleic acid vaccines allow for rapid response in the face of a pandemic, but bare nucleic acids are poorly stable and highly susceptible to degradation <xref rid="b0060" ref-type="bibr">[12]</xref>. Therefore, more advanced delivery platforms are urgently required to overcome these bottlenecks to advance the development of antiviral or bacterial vaccines.</p><p id="p0035">Biomaterials-based delivery systems have made tremendous progress in the last decade <xref rid="b0065" ref-type="bibr">[13]</xref>, especially biosafe and healthy biomaterials <xref rid="b0070" ref-type="bibr">[14]</xref>. The natural or synthetic polymers with biodegradability and great biocompatible can be used as carriers and adjuvants to deliver vaccine antigens and prevent the rapid degradation of antigens <xref rid="b0075" ref-type="bibr">[15]</xref>. Second, the controllably synthesized polymers can be transformed into different structures, including polymersomes, nanogels, micelles, microneedles (MNs), hydrogels, <italic toggle="yes">etc.</italic>, for various vaccination applications <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>. Surface-modified polymers can also be precisely targeted to the APC surface or within the cytoplasm and prolong the residence time of antigens in APCs, amplifying activation of APCs <xref rid="b0090" ref-type="bibr">[18]</xref>. Third, polymers act as immune adjuvants due to their inherent immunomodulatory capabilities, enhancing the immunogenicity of vaccines <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0100" ref-type="bibr">[20]</xref>. Moreover, polymers can also be modular, adopting the immunological cues of microorganisms by mimicking the biochemical properties of pathogens or forming hybrid biological-biomaterials to promote a robust and long-lasting protective immune response at the time of vaccination <xref rid="b0105" ref-type="bibr">[21]</xref>. Thus, immunologically effective biomaterials-enhanced vaccines are an excellent promising strategy against infection by pathogenic microorganisms.</p><p id="p0040">This review summarizes major viral and bacterial pathogens that cause epidemic transmission, including severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), influenza virus, hepatitis virus, HIV, <italic toggle="yes">S. pneumoniae</italic>, <italic toggle="yes">Mycobacterium tuberculosis</italic> (<italic toggle="yes">Mtb</italic>), <italic toggle="yes">E. coli</italic>, and <italic toggle="yes">Shigella</italic>. We described the characteristics of diseases associated with pathogenic infection and the applications of biomaterials-based vaccines for disease prevention (<xref rid="f0020" ref-type="fig">Scheme 1</xref>). In general, we mainly emphasized the efforts made by immunologically effective biomaterials to improve the safety, efficacy, and immunogenicity of vaccines to inform the development of vaccines.<fig id="f0020" position="float" orientation="portrait"><label>Scheme 1</label><caption><p>Immunologically effective biomaterials-enhanced vaccines against infection of pathogenic microorganisms. Biological materials are combined with immunogens to form vaccines that are phagocytosed and processed by APCs to induce robust and long-lasting humoral and cellular immunity to prevent infection by pathogenic microorganisms. Abbreviations: APC, antigen-presenting cell; CTL, cytotoxic T lymphocyte; DNA, deoxyribonucleic acid; <italic toggle="yes">E. coli</italic>, <italic toggle="yes">Escherichia coli</italic>; HIV, human immunodeficiency virus; <italic toggle="yes">Mtb</italic>, <italic toggle="yes">Mycobacterium tuberculosis</italic>; RNA, ribonucleic acid; <italic toggle="yes">S. pneumoniae</italic>, <italic toggle="yes">Streptococcus pneumoniae</italic>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="lk00020" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p></sec><sec id="s0010"><label>2</label><title>Immunologically effective biomaterials-enhanced vaccines against virus infection</title><p id="p0045">Infection caused by viruses is a major cause of health risks to human life. Although vaccines have advanced in the prevention of diseases like measles, there are still many diseases that require effective vaccines. Several functional biomaterials have demonstrated excellent vaccine carrier and adjuvant potentials, such as cationic polymers that significantly improve the immunogenicity of antiviral vaccines through electrostatic interactions with viral deoxyribonucleic acid (DNA) and efficient plasmid transfection capabilities in APCs <xref rid="b0110" ref-type="bibr">[22]</xref>. This section focuses on the limitation of existing vaccines against SARS-CoV-2, influenza virus, hepatitis virus, and HIV and the advantages of biomaterials-based vaccines (<xref rid="t0005" ref-type="table">Table 1</xref>).<table-wrap position="float" id="t0005" orientation="portrait"><label>Table 1</label><caption><p>Immunologically effective biomaterials-enhanced vaccines against virus infection.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Pathogenic virus</th><th colspan="1" rowspan="1">Vaccine type</th><th colspan="1" rowspan="1">Antigen</th><th colspan="1" rowspan="1">Polymer</th><th colspan="1" rowspan="1">Delivery system</th><th colspan="1" rowspan="1">Adjuvant</th><th colspan="1" rowspan="1">Route</th><th colspan="1" rowspan="1">Result</th><th colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="4" colspan="1">SARS-CoV-2</td><td colspan="1" rowspan="1">Nucleic acid vaccine</td><td colspan="1" rowspan="1">mRNA</td><td colspan="1" rowspan="1">Cationic biopolymer protamine</td><td colspan="1" rowspan="1">Hybrid biopolymer and lipid nanoparticle</td><td colspan="1" rowspan="1">&#8212;</td><td colspan="1" rowspan="1"><italic toggle="yes">i.m.</italic></td><td colspan="1" rowspan="1">The hybrid nanoparticle produced by the combination of protamine, DOTAP, and mRNA significantly improved the transfection efficiency of mRNA vaccines <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic>.</td><td colspan="1" rowspan="1"><xref rid="b0160" ref-type="bibr">[32]</xref></td></tr><tr><td colspan="1" rowspan="1">Nucleic acid vaccine</td><td colspan="1" rowspan="1">DNA encoding S or N protein</td><td colspan="1" rowspan="1">Deoxycholic acid conjugated low molecular weight PEI</td><td colspan="1" rowspan="1">SMN</td><td colspan="1" rowspan="1">TLR7/8 adjuvant R848</td><td colspan="1" rowspan="1"><italic toggle="yes">i.d.</italic></td><td colspan="1" rowspan="1">The isolable SMN patch stored at room temperature for 30&#160;days induced activation of CD4/8<sup>+</sup> T cells and induction of virus-specific IgG production.</td><td colspan="1" rowspan="1"><xref rid="b0180" ref-type="bibr">[36]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">RBD of SARS-CoV-2 spike protein</td><td colspan="1" rowspan="1">PEG-PLA</td><td colspan="1" rowspan="1">RBD subunit -<break/>CpG/Alum adjuvant-PNP hydrogel</td><td colspan="1" rowspan="1">CpG/Alum</td><td colspan="1" rowspan="1"><italic toggle="yes">s.c.</italic></td><td colspan="1" rowspan="1">The vaccine significantly enhanced the<break/>immunogenicity of RBD and induced neutralizing humoral immunity.</td><td colspan="1" rowspan="1"><xref rid="b0190" ref-type="bibr">[38]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">Spike protein of SARS-CoV-2</td><td colspan="1" rowspan="1">Copolymer P(Man-TLR7)</td><td colspan="1" rowspan="1">Spike-P(Man-TLR7) polymersome</td><td colspan="1" rowspan="1">Depot-forming adjuvant Alum</td><td colspan="1" rowspan="1"><italic toggle="yes">s.c.</italic></td><td colspan="1" rowspan="1">Spike-P(Man-TLR7) vaccination elicited robust antigen-specific humoral and cellular responses in mice.</td><td colspan="1" rowspan="1"><xref rid="b0195" ref-type="bibr">[39]</xref></td></tr><tr><td rowspan="9" colspan="1">Influenza virus</td><td colspan="1" rowspan="1">Inactivated vaccine</td><td colspan="1" rowspan="1">H1N1 A/New Caledonia/20/99 IVR116</td><td colspan="1" rowspan="1">P(NVA-<italic toggle="yes">co</italic>-AA)</td><td colspan="1" rowspan="1">&#8212;</td><td colspan="1" rowspan="1">Hyaluronic acid modified with tetraglycine-L-octaarginine</td><td colspan="1" rowspan="1"><italic toggle="yes">i.n.</italic></td><td colspan="1" rowspan="1">Polymer adjuvant co-administration with vaccine promoted IgA secretion.</td><td colspan="1" rowspan="1"><xref rid="b0240" ref-type="bibr">[48]</xref></td></tr><tr><td colspan="1" rowspan="1">Inactivated vaccine</td><td colspan="1" rowspan="1">H5N1 virus (A/EM/Korea/W149/06)</td><td colspan="1" rowspan="1">&#947;-PGA and CS</td><td colspan="1" rowspan="1">&#947;-PGA/CS nanoparticle</td><td colspan="1" rowspan="1">&#947;-PGA/CS</td><td colspan="1" rowspan="1"><italic toggle="yes">i.n.</italic></td><td colspan="1" rowspan="1">The &#947;-PGA/CS nanoparticle triggered high titers of IgG and IgA compared to other groups.</td><td colspan="1" rowspan="1"><xref rid="b0245" ref-type="bibr">[49]</xref></td></tr><tr><td colspan="1" rowspan="1">Inactivated vaccine</td><td colspan="1" rowspan="1">HA of H1N1, H3N2, B (Yamagata), and B (Victoria)</td><td colspan="1" rowspan="1">Polyoxidonium&#174;</td><td colspan="1" rowspan="1">&#8212;</td><td colspan="1" rowspan="1">Polyoxidonium&#174;</td><td colspan="1" rowspan="1"><italic toggle="yes">i.p.</italic></td><td colspan="1" rowspan="1">Grippol&#174; Quadrivalent activated DCs, T cells, and NK cells.</td><td colspan="1" rowspan="1"><xref rid="b0250" ref-type="bibr">[50]</xref></td></tr><tr><td colspan="1" rowspan="1">Inactivated vaccine</td><td colspan="1" rowspan="1">H1N1 (A/California/04/2009, CA04)</td><td colspan="1" rowspan="1"><break/>PLys-<italic toggle="yes">g</italic>-PPhe</td><td colspan="1" rowspan="1">&#8212;</td><td colspan="1" rowspan="1"><break/>PLys-<italic toggle="yes">g</italic>-PPhe</td><td colspan="1" rowspan="1"><italic toggle="yes">i.m.</italic></td><td colspan="1" rowspan="1">The cationic polymer adjuvant promoted Th1 and Th2 cellular immune responses.</td><td colspan="1" rowspan="1"><xref rid="b0255" ref-type="bibr">[51]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">HA of H1N1 (A/California/04/2009)</td><td colspan="1" rowspan="1">PEG-PLA</td><td colspan="1" rowspan="1">PEG-PLA nanoparticle hydrogel</td><td colspan="1" rowspan="1">TLR7/8 agonist imidazoquinoline</td><td colspan="1" rowspan="1"><italic toggle="yes">s.c.</italic></td><td colspan="1" rowspan="1">The PNP hydrogel prolonged the release of HA antigen.</td><td colspan="1" rowspan="1"><xref rid="b0265" ref-type="bibr">[53]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">HA of H1N1 (A/Brisbane/59/2007)</td><td colspan="1" rowspan="1">PEG-PLA</td><td colspan="1" rowspan="1">PEG-PLA nanoparticle hydrogel</td><td colspan="1" rowspan="1">TLR7/8 agonist imidazoquinoline</td><td colspan="1" rowspan="1"><italic toggle="yes">s.c.</italic></td><td colspan="1" rowspan="1">The PNP hydrogel triggered cross-protection of three different influenza virus strains.</td><td colspan="1" rowspan="1"><xref rid="b0270" ref-type="bibr">[54]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">HA of influenza A and H1N1 virus</td><td colspan="1" rowspan="1">Branched PEI and PLGA</td><td colspan="1" rowspan="1">PLGA-PEI VLP</td><td colspan="1" rowspan="1">TLR7/8 adjuvant R848 and RNA adjuvant PUUC</td><td colspan="1" rowspan="1"><italic toggle="yes">i.m.</italic></td><td colspan="1" rowspan="1">Vaccination with dual adjuvants increased percentage of CD8<sup>+</sup> T cells in the lungs and antigen-specific CD4<sup>+</sup> T cells in the spleen.</td><td colspan="1" rowspan="1"><xref rid="b0275" ref-type="bibr">[55]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">Protein from influenza A and H1N1 virus</td><td colspan="1" rowspan="1">Hydrophilic copolymer of dimethylaminoethyl methacrylate and pyridyl disulfide ethyl methacrylate</td><td colspan="1" rowspan="1">Nucleoprotein- nucleic acid adjuvant-nanoparticle</td><td colspan="1" rowspan="1">CpG DNA adjuvant</td><td colspan="1" rowspan="1"><italic toggle="yes">i.n.</italic></td><td colspan="1" rowspan="1">The vaccine activated APCs and rapidly generated protective CD8<sup>+</sup> Trms in the lung, which triggered long-term immune responses up to nine weeks.</td><td colspan="1" rowspan="1"><xref rid="b0280" ref-type="bibr">[56]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">HA and nucleoprotein antigens from H1N1 virus</td><td colspan="1" rowspan="1">Polyanhydride, Pluronic F127, and PDEAEM</td><td colspan="1" rowspan="1">Polyanhydride nanoparticle and pentablock PDEAEM copolymer micelle</td><td colspan="1" rowspan="1">Nanoparticle and micelle nanoadjuvant</td><td colspan="1" rowspan="1"><italic toggle="yes">s.c.</italic></td><td colspan="1" rowspan="1">Nanoadjuvants-assisted nanovaccines induced significant antibody titers in young and old mice.</td><td colspan="1" rowspan="1"><xref rid="b0285" ref-type="bibr">[57]</xref></td></tr><tr><td rowspan="4" colspan="1">HBV</td><td colspan="1" rowspan="1">Nucleic acid vaccine</td><td colspan="1" rowspan="1">DNA encoding HBsAg</td><td colspan="1" rowspan="1">PDMAEMA, P&#946;AE, and &#946;-glucan</td><td colspan="1" rowspan="1">PDMAEMA:P&#946;AE polymersome with or without &#946;-glucan</td><td colspan="1" rowspan="1">&#946;-glucan</td><td colspan="1" rowspan="1"><italic toggle="yes">s.c.</italic></td><td colspan="1" rowspan="1">The polymersome together with &#946;-glucan improved the transfection efficiency of DNA encoding HBsAg <italic toggle="yes">in vitro</italic>.</td><td colspan="1" rowspan="1"><xref rid="b0305" ref-type="bibr">[61]</xref></td></tr><tr><td colspan="1" rowspan="1">Nucleic acid vaccine</td><td colspan="1" rowspan="1">DNA encoding HBsAg</td><td colspan="1" rowspan="1">Cationic polymersomes, including PEI, PDMAEMA, and P(DMAEMA-<italic toggle="yes">co</italic>-MAA)</td><td colspan="1" rowspan="1">Cationic polymers-DNA polymersomes</td><td colspan="1" rowspan="1">PEI, PDMAEMA, and P(DMAEMA-<italic toggle="yes">co</italic>-MAA)</td><td colspan="1" rowspan="1"><italic toggle="yes">i.m.</italic></td><td colspan="1" rowspan="1">Among many polymers, cationic polymers were able to increase the transfection efficiency of HBsAg DNA <italic toggle="yes">in vivo</italic> and induced a shift of the immune response toward Th1-mediated immunity.</td><td colspan="1" rowspan="1"><xref rid="b0310" ref-type="bibr">[62]</xref></td></tr><tr><td colspan="1" rowspan="1">Nucleic acid vaccine</td><td colspan="1" rowspan="1">DNA encoding HBsAg</td><td colspan="1" rowspan="1">Man-CS-Phe micelle</td><td colspan="1" rowspan="1">Man-CS-Phe micelle</td><td colspan="1" rowspan="1">&#8212;</td><td colspan="1" rowspan="1"><italic toggle="yes">i.d.</italic></td><td colspan="1" rowspan="1">Mannose receptor-mediated cell uptake and high <italic toggle="yes">in vitro</italic> transfection efficiency were demonstrated in RAW 264.7 and DC2.4 cells, and multifold serum antibody titers were induced <italic toggle="yes">in vivo</italic>.</td><td colspan="1" rowspan="1"><xref rid="b0315" ref-type="bibr">[63]</xref></td></tr><tr><td colspan="1" rowspan="1">Nucleic acid vaccine</td><td colspan="1" rowspan="1">HBV recombinant plasmid<break/>encoding HBsAg</td><td colspan="1" rowspan="1">APS</td><td colspan="1" rowspan="1">&#8212;</td><td colspan="1" rowspan="1">APS</td><td colspan="1" rowspan="1">&#8212;</td><td colspan="1" rowspan="1">APS acted as an immune adjuvant to enhance the immune effect of HBV DNA vaccine by promoting DC maturation and suppressing Tregs.</td><td colspan="1" rowspan="1"><xref rid="b0320" ref-type="bibr">[64]</xref></td></tr><tr><td rowspan="2" colspan="1">HCV</td><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">Recombinant monomeric E2 protein</td><td colspan="1" rowspan="1">PCPP</td><td colspan="1" rowspan="1">R848-PCPP-E2 polymersome</td><td colspan="1" rowspan="1">TLR7/8 adjuvant R848 and PCPP</td><td colspan="1" rowspan="1"><italic toggle="yes">i.p.</italic></td><td colspan="1" rowspan="1">R848-PCPP-E2 complex induced higher neutralization titers and promoted balanced Th1/Th2 reactions.</td><td colspan="1" rowspan="1"><xref rid="b0345" ref-type="bibr">[69]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">Recombinant monomeric E2 protein</td><td colspan="1" rowspan="1">PCPP and PCEP</td><td colspan="1" rowspan="1">PCPP-E2 or PCEP-E2 polymersome</td><td colspan="1" rowspan="1">PCPP and PCEP</td><td colspan="1" rowspan="1"><italic toggle="yes">i.p.</italic></td><td colspan="1" rowspan="1">The immunoadjuvant PCEP induced significantly higher HCV-specific IgG titers in mice compared to PCPP, Alum, and addavax.</td><td colspan="1" rowspan="1"><xref rid="b0355" ref-type="bibr">[71]</xref></td></tr><tr><td rowspan="6" colspan="1">HIV</td><td colspan="1" rowspan="1">Subunit/peptide vaccine</td><td colspan="1" rowspan="1">HIV Env V3 oligomannose-9 glycopeptide</td><td colspan="1" rowspan="1">PHPMA and PAMAM</td><td colspan="1" rowspan="1">PHPMA-based polymer extending from PAMAM core</td><td colspan="1" rowspan="1">TLR7/8 agonist 2Bxy</td><td colspan="1" rowspan="1"><italic toggle="yes">s.c</italic>./<italic toggle="yes">i.m.</italic>/<italic toggle="yes">i.v.</italic></td><td colspan="1" rowspan="1">In non-human primate studies, an optimized immunogen was found to be recognized by Env V3/bNAbs, significantly increasing the antibody binding potency at the V3 site.</td><td colspan="1" rowspan="1"><xref rid="b0375" ref-type="bibr">[75]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit/peptide vaccine</td><td colspan="1" rowspan="1">HIV PCS5 peptide</td><td colspan="1" rowspan="1">Polysaccharides (CS or hyaluronic acid)</td><td colspan="1" rowspan="1">Polysaccharides-PCS5-polyI:C</td><td colspan="1" rowspan="1">TLR3 agonist polyI:C</td><td colspan="1" rowspan="1"><italic toggle="yes">i.m.</italic></td><td colspan="1" rowspan="1">All vaccine systems successfully induced humoral immune responses with different T cell responses.</td><td colspan="1" rowspan="1"><xref rid="b0380" ref-type="bibr">[76]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">HIV Env gp120</td><td colspan="1" rowspan="1">HBP comprising poly(dimethyl acrylamide)</td><td colspan="1" rowspan="1">HBP-TLR7/8 agonist-gp120</td><td colspan="1" rowspan="1">TLR7/8 agonist</td><td colspan="1" rowspan="1"><italic toggle="yes">s.c.</italic></td><td colspan="1" rowspan="1">Vaccines containing hyperbranched polymer adjuvants significantly increased IgG2c titers in mice and induced a strong Th1 cell-induced immune response.</td><td colspan="1" rowspan="1"><xref rid="b0390" ref-type="bibr">[78]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">HIV Env BG505 SOSIP and MD39 gp140 trimer</td><td colspan="1" rowspan="1">PAA-supporting silk fibroin protein</td><td colspan="1" rowspan="1">PAA-silk fibroin protein-Env trimer-adjuvant MN</td><td colspan="1" rowspan="1">TLR2 agonist Pam3CSK4/TLR3 agonist polyI:C</td><td colspan="1" rowspan="1"><italic toggle="yes">i.d.</italic> injection or MN implantation</td><td colspan="1" rowspan="1">MN implantation induced a 300-fold increase in serum IgG titers and a 16-fold increase in bone marrow plasma cells compared to <italic toggle="yes">i.d.</italic> injection.</td><td colspan="1" rowspan="1"><xref rid="b0395" ref-type="bibr">[79]</xref></td></tr><tr><td colspan="1" rowspan="1">Nucleic acid vaccine</td><td colspan="1" rowspan="1">DNA encoding HIV-1 core antigen</td><td colspan="1" rowspan="1">PEG-<italic toggle="yes">g</italic>-PEI</td><td colspan="1" rowspan="1">PEG-<italic toggle="yes">g</italic>-PEI/DNA nanoparticle-in-PLGA microsphere</td><td colspan="1" rowspan="1">&#8212;</td><td colspan="1" rowspan="1"><italic toggle="yes">i.m.</italic></td><td colspan="1" rowspan="1">The mixed two-particle nanospheres induced significant humoral and cellular immunity in mice at low doses.</td><td colspan="1" rowspan="1"><xref rid="b0400" ref-type="bibr">[80]</xref></td></tr><tr><td colspan="1" rowspan="1">Nucleic acid vaccine</td><td colspan="1" rowspan="1">AIR.tHIVconsv1/2 saRNA</td><td colspan="1" rowspan="1">PEI</td><td colspan="1" rowspan="1">PEI-saRNA</td><td colspan="1" rowspan="1">&#8212;</td><td colspan="1" rowspan="1"><italic toggle="yes">i.m.</italic></td><td colspan="1" rowspan="1">The saRNA vaccine induced memory T cells that remained at elevated level for 22&#160;weeks after administration.</td><td colspan="1" rowspan="1"><xref rid="b0415" ref-type="bibr">[83]</xref></td></tr><tr><td rowspan="3" colspan="1">HPV</td><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">Peptide epitopes from HPV16 capsid protein L2</td><td colspan="1" rowspan="1">PLGA</td><td colspan="1" rowspan="1">Peptide epitopes-Q&#946;-PLGA</td><td colspan="1" rowspan="1">&#8212;</td><td colspan="1" rowspan="1">MN implantation</td><td colspan="1" rowspan="1">The single-dose vaccine produced IgG antibody levels in mice comparable to those of the traditional injectable vaccines.</td><td colspan="1" rowspan="1"><xref rid="b0455" ref-type="bibr">[91]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">RG1-VLP</td><td colspan="1" rowspan="1">PCEP</td><td colspan="1" rowspan="1">RG1-VLP-PCEP</td><td colspan="1" rowspan="1">PCEP</td><td colspan="1" rowspan="1"><italic toggle="yes">i.m.</italic></td><td colspan="1" rowspan="1">The VLP vaccine doses adjuvanted by PCEP could be reduced by 75% without reducing the level of vaccine immunity.</td><td colspan="1" rowspan="1"><xref rid="b0460" ref-type="bibr">[92]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">RG1-VLP</td><td colspan="1" rowspan="1">PCMP</td><td colspan="1" rowspan="1">RG1-VLP-PCMP</td><td colspan="1" rowspan="1">PCMP</td><td colspan="1" rowspan="1"><italic toggle="yes">i.m.</italic></td><td colspan="1" rowspan="1">PCMP elicited stronger humoral immunity, especially high levels of cross-neutralizing antibodies compared to conventional adjuvants.</td><td colspan="1" rowspan="1"><xref rid="b0465" ref-type="bibr">[93]</xref></td></tr><tr><td colspan="1" rowspan="1">Ebola virus<break/></td><td colspan="1" rowspan="1">Nucleic acid vaccine</td><td colspan="1" rowspan="1">DNA encoding artificial T cell immunogen</td><td colspan="1" rowspan="1">PAMAM and PG</td><td colspan="1" rowspan="1">PG-DNA</td><td colspan="1" rowspan="1">&#8212;</td><td colspan="1" rowspan="1"><italic toggle="yes">i.m.</italic></td><td colspan="1" rowspan="1">The immunogenicity of DNA vaccine containing PG was higher than that of negative control.</td><td colspan="1" rowspan="1"><xref rid="b0480" ref-type="bibr">[96]</xref></td></tr><tr><td colspan="1" rowspan="1">Dengue virus</td><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">Dengue virus EDIII</td><td colspan="1" rowspan="1">P&#946;AE, PAA, and PNHP</td><td colspan="1" rowspan="1">P&#946;AE/PAA/EDIII</td><td colspan="1" rowspan="1">PolyI:C and Pam3CSK4</td><td colspan="1" rowspan="1">MN implantation</td><td colspan="1" rowspan="1">The vaccine had continuous released antigen and adjuvant within two weeks.</td><td colspan="1" rowspan="1"><xref rid="b0505" ref-type="bibr">[101]</xref></td></tr><tr><td colspan="1" rowspan="1">Zika virus</td><td colspan="1" rowspan="1">Inactivated vaccine</td><td colspan="1" rowspan="1">Inactivated Zika virus</td><td colspan="1" rowspan="1">CS and &#947;-PGA</td><td colspan="1" rowspan="1">Inactivated Zika virus-CS-&#947;-PGA nanoparticle</td><td colspan="1" rowspan="1">CS and &#947;-PGA</td><td colspan="1" rowspan="1"><italic toggle="yes">s.c.</italic></td><td colspan="1" rowspan="1">The vaccines induced both anti-Zika virus IgG1 and IgG2a antibodies and generated balanced Th1/2 responses in mice.</td><td colspan="1" rowspan="1"><xref rid="b0520" ref-type="bibr">[104]</xref></td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: Alum, aluminium; APCs, antigen-presenting cells; APS, astragalus polysaccharide; bNAbs, broadly neutralizing antibodies; CS, chitosan; DCs, dendritic cells; DNA, deoxyribonucleic acid; DOTAP, dioleoyl-3-trimethylammonium propane; EDIII, Env Domain III; Env, Envelope glycoprotein; HA, hemagglutinin; HBP, hyperbranched polymer; HBsAg, hepatitis B surface antigens;&#160;HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HPV, human papillomavirus; <italic toggle="yes">i.d.</italic>, intradermal injection; IgA, immunoglobulin A; IgG, immunoglobulin G; <italic toggle="yes">i.m.</italic>, intramuscular injection; <italic toggle="yes">i.n.</italic>, intranasal injection; <italic toggle="yes">i.p.</italic>, intraperitoneal injection; <italic toggle="yes">i.v.</italic>, intravenous injection; Man-CS-Phe, mannosylated phenylalanine grafted chitosan; mRNA, messenger ribonucleic acid; NK cells, natural killer cells; PAA, poly(acrylic acid); Pam3CSK4, porphyromonas gingivalis lipopolysaccharide and lipoteichoic acid; PAMAM, polyamidoamine; PCEP, poly(di(carboxylatoethylphenoxy)phosphazene); PCMP, poly(di(carboxylatomethylphenoxy)phosphazene); PCPP, poly(di(carboxylatophenoxy)phosphazene); PCS5, protease cleavage site 5; PDEAEM, poly(diethylaminoethyl methacrylate); P(DMAEMA-<italic toggle="yes">co</italic>-MAA), poly(2-(dimethylamino)ethyl methacrylate-<italic toggle="yes">co</italic>-methacrylic acid); PEG-PLA, poly(ethylene glycol)-<italic toggle="yes">block</italic>-poly(lactic acid); PEI, poly(ethylene imine); PG, polyglucin:spermidine conjugate; PHPMA, poly(<italic toggle="yes">N</italic>-(2-hydroxypropyl) methacrylamide); PLGA, poly(lactic-<italic toggle="yes">co</italic>-glycolic acid); PLys-<italic toggle="yes">g</italic>-PPhe, poly(L-lysine)-<italic toggle="yes">graft</italic>-poly(L-phenylalanine); P(Man-TLR7), poly(mannose-<italic toggle="yes">co</italic>-imidazoquinoline toll-like receptor 7); PNHP, poly(<italic toggle="yes">O</italic>-nitrobenzylmethacrylate-<italic toggle="yes">co</italic>-(hydroxyethyl methacrylate)-<italic toggle="yes">co</italic>-(poly(ethylene glycol) methacrylate)); PNP, polymer nanoparticle; P(NVA-<italic toggle="yes">co</italic>-AA), poly(<italic toggle="yes">N</italic>-vinylacetamide-<italic toggle="yes">co</italic>-acrylic acid); PolyI:C, Poly(inosinic:cytidylic acid); PUUC, retinoic acid-inducible gene-I protein (RIG-I); P&#946;AE, poly(&#946;-amino ester); R848, resiquimod; RAW, mouse mononuclear macrophage; RBD, receptor-binding domain; RG1-VLP, HPV16L1-16L2 virus-like particle; saRNA, self-amplifying messenger&#160;ribonucleic acid; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; <italic toggle="yes">s.c.</italic>, subcutaneous injection; SMN, separable microneedle; Th1/2, helper T cells 1/2; TLR, toll-like receptor; Tregs, regulatory T cells; Trms, tissue resident memory T cells; V3, Variable loop 3;&#160;VLP, viral-like particle; &#947;-PGA, &#947;-polyglutamic acid.</p></fn></table-wrap-foot></table-wrap></p><sec id="s0015"><label>2.1</label><title>COVID-19</title><p id="p0050">SARS-CoV-2, the pathogen of COVID-19, is an enveloped, single-stranded RNA virus composed of four structural proteins, namely spike (S), membrane (M), envelope (E), and nucleocapsid (N) <xref rid="b0115" ref-type="bibr">[23]</xref>. As a member of the human betacoronavirus family, SARS-CoV-2 has caused an unprecedented scale of infection compared to other classes, such as SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). Mass vaccination has become the primary means of preventing population-to-population transmission of SARS-CoV-2. The WHO has listed more than 100 candidate vaccines against different structures of antigenic proteins and nucleic acids encoding antigens in preclinical development <xref rid="b0120" ref-type="bibr">[24]</xref>, and some vaccines have already been approved by the US Food and Drug Administration (FDA), such as two messenger ribonucleic acid (mRNA)-formulated vaccines developed by Pfizer-BioNTech <xref rid="b0125" ref-type="bibr">[25]</xref>. However, rapid approval to market has left a legacy of problems for SARS-CoV-2 vaccines, such as expensive production costs, harsh shipping conditions, and weak immunogenicity <xref rid="b0130" ref-type="bibr">[26]</xref>. Therefore, there is an urgent need for more advanced vaccine platforms. To date, more than 26 candidate nanovaccines have entered clinical trials that demonstrated the outstanding potential of biomaterials-based vaccines against SARS-CoV-2 <xref rid="b0135" ref-type="bibr">[27]</xref>.</p><p id="p0055">A representative one is the FDA-approved BioNTech/Pfizer BNT162b2 nucleic acid vaccine, a lipid nanoparticle-encapsulated mRNA vaccine encoding the S protein of SARS-CoV-2 <xref rid="b0125" ref-type="bibr">[25]</xref>. The effectiveness rate of more than 95% has led to the widespread promotion of mRNA vaccine in times of emergency <xref rid="b0140" ref-type="bibr">[28]</xref>. However, the cold-chain storage conditions of -80 or -20&#160;&#176;C make the application difficult in economically disadvantaged areas <xref rid="b0145" ref-type="bibr">[29]</xref>. A vaccine based on polymer-delivered mRNA was developed to optimize the lyophilization method of mRNA, relax preservation conditions, and reduce costs <xref rid="b0150" ref-type="bibr">[30]</xref>. The nanoparticle formed by the complexation of cationic poly(&#946;-amino ester) (P&#946;AE) with mRNA demonstrated the potential to combat the infection of SARS-CoV-2.</p><p id="p0060">Furthermore, cationic nanoparticle delivery of mRNA can modulate the transfection rate of vaccines. One promising strategy is the synthesis of lipid-cationic polymer hybrid nanoparticles for the delivery of mRNA vaccine of SARS-CoV-2 <xref rid="b0155" ref-type="bibr">[31]</xref>. Using the unique physicochemical properties of two materials, the construction of composite material will improve the transfection efficiency of mRNA vaccines and throttle down the source. For example, Siewert <italic toggle="yes">et al.</italic> designed a hybrid nanoparticle combining protamine and dioleoyl-3-trimethylammonium propane <xref rid="b0160" ref-type="bibr">[32]</xref>. Compared to a single complexing agent, the hybrid biopolymer-lipid nanoparticle significantly improved mRNA transfection capacity into immune cells, promoting the immune efficacy of vaccines. This improvement may arise due to the different structural morphologies and surface composition of the combined materials, which lead to a difference in mRNA release when self-assembled with the complexing material. Therefore, composite structure formed by various materials is worth considering to alleviate the high cost and difficult transfer of existing mRNA vaccines against SARS-CoV-2.</p><p id="p0065">In addition to conventional mRNA vaccines, other types of nucleic acid vaccines, such as self-amplifying mRNA (saRNA) and DNA vaccines, are also candidates for preventing COVID-19 <xref rid="b0165" ref-type="bibr">[33]</xref>. These nucleic acid-based vaccines are negatively charged macromolecules that enter immune cells only in a delivery system, such as cationic polymers, dendrimers, nanogels, and polymersomes <xref rid="b0170" ref-type="bibr">[34]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>. The electrostatic interaction between nucleic acids and positively charged biomaterial complexes forms stable vaccines for long-term immune response. For example, Yin <italic toggle="yes">et al.</italic> developed a separable microneedle (SMN) patch for delivery of low molecular weight poly(ethylene imine) (PEI) nanoparticle that encapsulated DNA encoding S or N protein of the SARS-CoV-2 and resiquimod (R848), an immunostimulant, which activates APCs through toll-like receptor 7/8 (TLR7/8)-dependent signal pathway (<xref rid="f0005" ref-type="fig">Fig. 1</xref>) <xref rid="b0180" ref-type="bibr">[36]</xref>. After vaccination, the backing layer of SMN detached through the change in hydrophobicity of SMN under low temperature (14&#8211;16&#160;&#176;C) conditions, allowing the SMN to remain in the skin in direct contact with APCs in the dermis. The SMN patch with DNA vaccine could be preserved at room temperature for at least 30&#160;days without a reduced immune response. On the one hand, this continuous delivery allows the recruitment of more APCs. On the other hand, the nanoparticles released from SMN diffuse into the lymph nodes to present antigens. As a result, intradermal injection of nanovaccine-loaded SMN significantly increased CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, and the level of virus-specific immunoglobulin G (IgG) <xref rid="b0180" ref-type="bibr">[36]</xref>. These results illustrate the value of easily synthesized polymers as carriers in improving the performance of approved nucleic acid vaccines, encompassing the efficiency of vaccination, the durability of the immune response, and the versatility of storage conditions.<fig id="f0005" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>SMN patch for delivery of DNA nanovaccine against COVID-19. A) Synthetic scheme of nanovaccine. B) Thermo-responsiveness alters the hydrophobicity of SMN, allowing the SMN backing layer to detach and the SMN to remain in the skin. C&#8211;F) Percentages of CD8<sup>+</sup>IFN-&#947;<sup>+</sup>, CD8<sup>+</sup>IL-2<sup>+</sup>, CD4<sup>+</sup>IFN-&#947;<sup>+</sup>, and CD4<sup>+</sup>IL-2<sup>+</sup> T cells in spleen after vaccination. Reproduced with permission <xref rid="b0180" ref-type="bibr">[36]</xref>. Copyright 2021, American Chemical Society. Abbreviations: DA-LPEI, deoxycholic acid conjugated low molecular weight poly(ethylene imine); DLP-R, DA-LPEI-R848; DLP-RS, DA-LPEI-R848 with pCOV-S; DLP-RN, DA-LPEI-R848 with pCOV-N; DNA, deoxyribonucleic acid; pCOV-S or pCOV-N, plasmid encoding S or N protein; PNPAM-B, poly(<italic toggle="yes">N</italic>-isopropylacrylamide-<italic toggle="yes">co</italic>-butyl acrylate); PVA, poly(vinyl acetate); SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SMN, separable microneedle.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="lk00005" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0070">Moreover, another promising vaccine against SARS-CoV-2 infection is subunit vaccine. Although there is no commercially approved subunit vaccine against COVID-19, biomaterials-based vaccines further promote the development of subunit vaccines by improving the immunogenicity of vaccine. First, biomaterials achieve co-delivery of antigens with immune adjuvants, triggering the body to produce more neutralizing antibodies with increased immunogenicity. For instance, the receptor-binding domain (RBD) of SARS-CoV-2 S protein binds to the angiotensin-converting enzyme 2 (ACE2) receptor to mediate virus entry into cells <xref rid="b0115" ref-type="bibr">[23]</xref>. Due to high productivity and stability, RBD is a suitable target antigen for the COVID-19 subunit vaccine. However, RBD has poor immunogenicity and is not ideal as a vaccine antigen alone <xref rid="b0185" ref-type="bibr">[37]</xref>. Recently, Gale <italic toggle="yes">et al.</italic> introduced an injectable polymer nanoparticle (PNP) hydrogel with an RBD subunit vaccine containing CpG/aluminum (CpG/Alum) adjuvant complex <xref rid="b0190" ref-type="bibr">[38]</xref>. As a sustained release system, the PNP hydrogel slowly delivered the RBD subunit vaccine and the released adjuvant, allowing more APCs to be recruited into the hydrogel. This platform initiated adaptive immunity and produced large amounts of anti-RBD IgG, significantly enhancing the immunogenicity of RBD subunit vaccine against SARS-CoV-2 infection.</p><p id="p0075">Second, in addition to the co-delivery of antigen and immune adjuvant, coupling the two components to form an antigen-adjuvant copolymer is another way to enhance vaccine immunogenicity. For example, Gray <italic toggle="yes">et al.</italic> combined mannose with TLR7 agonist into a copolymer, which was then conjugated with full-length S protein of SARS-CoV-2 to produce Spike-P(Man-TLR7) vaccine <xref rid="b0195" ref-type="bibr">[39]</xref>. Specifically, the mannose component of copolymer targeted the C-type lectin on the surface of APCs for precise delivery <xref rid="b0200" ref-type="bibr">[40]</xref>. Then, APCs were effectively activated by the synergistic effect of copolymer TLR7 agonist. Interestingly, the full-length S protein-based subunit vaccine in this system elicited stronger humoral immunity than the RBD vaccine, sufficient to meet FDA approval requirements <xref rid="b0195" ref-type="bibr">[39]</xref>. The possible reason is that the RBD antigen is smaller than the full-length S protein, and its binding sites to ACE2 are easily and completely obscured by P(Man-TLR7) <xref rid="b0205" ref-type="bibr">[41]</xref>. The Spike-P(Man-TLR7) stimulated cellular immunity that increased the follicular helper T cells, CD4<sup>+</sup> T cells, and CD8<sup>+</sup> T cells and elicited strong humoral immunity <xref rid="b0195" ref-type="bibr">[39]</xref>. This demonstrates that biomaterials-based vaccines improve the immunogenicity of subunit vaccines against SARS-CoV-2. Meanwhile, a suitable delivery platform of vaccines needs to be selected according to the physicochemical properties of biomaterial itself and the characteristics of antigenic proteins.</p><p id="p0080">Overall, biomaterials-based vaccines provide new ideas for fighting SARS-CoV-2. On the one hand, more advanced synthetic techniques and a variety of material options address the challenges of preserving the cold chain of existing vaccines. At the same time, biomaterials enhance the immunogenicity of vaccines and stimulate a more robust immune response. There are still some obstacles to overcome. The mRNA-lipid nanoparticle vaccines currently promoted in the market suffer from rare but severe allergic reactions attributed to the lipid component of poly(ethylene glycol)2000 (PEG2000) in the composition <xref rid="b0210" ref-type="bibr">[42]</xref>. Novel materials could be developed to replace PEG to reduce allergy, such as polyphosphoesters <xref rid="b0215" ref-type="bibr">[43]</xref>.</p></sec><sec id="s0020"><label>2.2</label><title>Influenza</title><p id="p0085">Influenza is a respiratory infectious disease, and the primary causative pathogen of which is the influenza virus belonging to the Orthomyxoviridae family of RNA viruses, divided into types A, B, and C <xref rid="b0220" ref-type="bibr">[44]</xref>. Influenza viruses contain a negative-stranded RNA genome that is highly susceptible to point mutations in antigenicity-determining regions. These mutations contribute to the diversity of influenza virus strains, like antigenic shift and viral evasion of preexisting immune recognition, resulting in pandemics <xref rid="b0225" ref-type="bibr">[45]</xref>. While medications are available to treat influenzas, such as oseltamivir and curcumin <xref rid="b0230" ref-type="bibr">[46]</xref>, vaccination remains the central means of preventing the spread of influenza.</p><p id="p0090">Currently, most influenza vaccines are injectable inactivated vaccines. These vaccines induce humoral immunity through intramuscular or subcutaneous administration, producing high titers of IgG antibodies to neutralize the influenza pathogen. IgG in the serum stops the worsening of symptoms after infection with the influenza virus but cannot prevent disease at the site of infection (<italic toggle="yes">i.e.</italic>, the mucous membranes of respiratory tract) <xref rid="b0235" ref-type="bibr">[47]</xref>. In contrast, intranasal immunity protects the mucosa by inducing secretory IgA. The participation of biomaterial is particularly critical in this route of administration. They can be used as a mucosal adjuvant to prevent virus proliferation and protect the host <xref rid="b0240" ref-type="bibr">[48]</xref>, <xref rid="b0245" ref-type="bibr">[49]</xref>. Tanishita <italic toggle="yes">et al.</italic> found that immunized mice intranasally with inactivated H1N1 virus showed significant weight loss after infection with H1N1 A/Puerto Rico/8/34 (PR8) strain <xref rid="b0240" ref-type="bibr">[48]</xref>. On the contrary, there were few signs associated with a viral infection for mice inoculated with a mixture of viral antigen and tetraglycine-<sc>l</sc>-octaarginine-linked hyaluronic acid. This is mainly because hyaluronic acid mucosal adjuvant highly induces IgG and IgA, which are capable of cross-reacting with the PR8 virus. Therefore, biomaterial adjuvants are of significant value in changing the route of administration to promote a more robust humoral immune response.</p><p id="p0095">Furthermore, inactivated vaccines that primarily induce humoral immunity have low cross-protective immunity against various subtypes of influenza viruses. Cell-mediated immunity provides broad strain-specific protection and is more cross-reactive than humoral immunity <xref rid="b0235" ref-type="bibr">[47]</xref>. Coadministration of biomaterials-based immune adjuvants with vaccines induces strong humoral and cellular immunity. Grippol&#174; Quadrivalent (GQ), a commercially available vaccine, consists of Polyoxidonium&#174; adjuvant and recombinant hemagglutinin (HA) from four subtypes of influenza virus strains (H1N1, H3N2, B (Yamagata), and B (Victoria)) <xref rid="b0250" ref-type="bibr">[50]</xref>. Administered to mice, the GQ vaccine induced HA antibodies and stimulated the activity of dendritic cells (DCs), CD4<sup>+</sup> T cells, and natural killer (NK) cells. Specifically, the antigenic dose of GQ is 1/3 of the standard WHO dose, which implies strong immunogenicity of the polymer adjuvant with the vaccine <xref rid="b0250" ref-type="bibr">[50]</xref>. In a separate study, squalene-based cationic poly(amino acid) adjuvants co-administered with inactivated H1N1 vaccine also significantly promoted antigen-specific antibody and T cell immune responses and prevented influenza symptoms in mice <xref rid="b0255" ref-type="bibr">[51]</xref>.</p><p id="p0100">Biomaterials-based adjuvants improve the cross-protection of inactivated vaccines against influenza virus infection. However, given the safety concerns for inactivated vaccines and the progress in production processes, subunit influenza vaccines have been developed and implemented <xref rid="b0260" ref-type="bibr">[52]</xref>. Typically, subunit vaccines are less immunogenic than inactivated vaccines. Biomaterials enhance the immunogenicity of influenza vaccines by providing effective long-term protection and memory immune responses.</p><p id="p0105">One strategy is to inject hydrogels for continuous delivery of influenza HA antigen and immune adjuvant. Saouaf <italic toggle="yes">et al.</italic> reported that the PNP hydrogel platform containing TLR7/8 agonist and HA antigen significantly prolonged the release time of vaccine with high titers of IgG antibodies in mice up to 56&#160;days after injection <xref rid="b0265" ref-type="bibr">[53]</xref>. Meanwhile, Roth <italic toggle="yes">et al.</italic> observed that this PNP hydrogel platform produced cross-protective immunity against different influenza virus mutants <xref rid="b0270" ref-type="bibr">[54]</xref>. Compared to delivery with Alum adjuvant, the PNP hydrogel platform induced 256-fold, 64-fold, and 16-fold higher IgG antibody titers against influenza variants A/California/07/2009(H1N1), A/Michigan/45/2015(H1N1), and PR8 strains, respectively. Therefore, the PNP hydrogel significantly expands the magnitude and effectiveness width of humoral immune response and allows for a reduction in the dose of antigen.</p><p id="p0110">An alternative strategy involves using biomaterials to improve the immunogenicity of influenza subunit vaccines by inducing long-lasting memory cellular immunity. Biomaterials mediate the retention of antigens in APCs and promote APC maturation. They also promote the production of tissue-resident memory T cells (Trms), which rapidly protect the lungs from influenza. For instance, Toy <italic toggle="yes">et al.</italic> designed the pathogen-like nanoparticle assembled from the H1N1 HA antigen, adjuvant, poly(lactic-<italic toggle="yes">co</italic>-glycolic acid) (PLGA), and PEI <xref rid="b0275" ref-type="bibr">[55]</xref>. The adjuvant R848 and retinoic acid-inducible gene-I protein (RIG-I, PUUC) of nanovaccine targeted the endosomes and cytoplasm of APCs, respectively, and simultaneously activated TLR7/8 and RIG-I pathways, contributing to long-term effective cellular memory immunity. In another study, based on the principle of pH-dependent endosomal escape for precise cytoplasmic delivery of antigen and major histocompatibility type I molecule (MHC-I) processing, Knight <italic toggle="yes">et al.</italic> designed a pH-responsive nanoparticle vaccine <xref rid="b0280" ref-type="bibr">[56]</xref>. In the mice model, the nanoparticle vaccine recruited large numbers of antigen-specific Trms in the lung and successfully resisted influenza virus invasion for up to nine weeks.</p><p id="p0115">Biomaterials-based influenza vaccines also enhance innate and adaptive immunity in special populations, such as the elderly, and are a promising influenza vaccine technology for immunocompromised populations. For example, Ross <italic toggle="yes">et al.</italic> developed a nanovaccine that combined two polymer adjuvants, polyanhydride nanoparticle and pentablock copolymer micelle <xref rid="b0285" ref-type="bibr">[57]</xref>. The nanovaccine enhanced <italic toggle="yes">in vitro</italic> activation of isolated DCs in elderly mice and induced specific antibodies, offering hope for influenza vaccines in immunocompromised people.</p><p id="p0120">The most challenging bottleneck facing influenza vaccines is the high mutation rate of influenza viruses that causes antigenic drift. Therefore, promising influenza vaccines must be able to induce cross-protective immunity against different strains. Biomaterials are widely used in influenza vaccines. Acting as immune adjuvants, biomaterials significantly boost humoral immune responses and induce cellular immunity when co-immunized with influenza vaccines. At the same time, biomaterials induced sustained and memory cross-protective immunity to influenza mutant infection by prolonging the release of antigens and expanding APC activation.</p></sec><sec id="s0025"><label>2.3</label><title>Hepatitis</title><p id="p0125">Viral infection causes five types of hepatitis, A, B, C, D, and E, notably B and C subtypes, which causes persistent disease in many individuals, even cirrhosis and liver cancer <xref rid="b0290" ref-type="bibr">[58]</xref>. Although viral suppressor drugs, such as nucleoside analogs, have been developed, current treatments do not completely eradicate the hepatitis virus <xref rid="b0295" ref-type="bibr">[59]</xref>. The development of prophylactic and therapeutic vaccines remains the primary strategy to eliminate the viruses. The existing vaccines carried out mainly against hepatitis B virus (HBV), such as the commercially available Engerix-B (yeast recombinant hepatitis B surface antigens (HBsAg)) recombinant vaccine, lack effective cross-reactivity. Moreover, the vaccine does not, or only induce weak antigen-specific T cell responses and is ineffective or less effective in patients with chronic hepatitis <xref rid="b0300" ref-type="bibr">[60]</xref>. Polymer-based vaccines lift these limitations. Therefore, they are promising anti-hepatitis virus vaccines.</p><p id="p0130">Biomaterials-based DNA vaccine is a powerful tool to prevent chronic hepatitis B. The main barriers to DNA vaccines encoding HBsAg are low transfection rates and transient antigen expression of antigens. Cationic polymers, such as chitosan (CS), poly(2-(dimethylamino) ethyl methacrylate) (PDMAEMA), P&#946;AE, and linear PEI, have all been reported to improve the delivery and transfection efficiency of DNA vaccines encoding HBsAg in APCs and enhance immunogenicity as immune adjuvants <xref rid="b0305" ref-type="bibr">[61]</xref>, <xref rid="b0310" ref-type="bibr">[62]</xref>, <xref rid="b0315" ref-type="bibr">[63]</xref>. In a study, Bos <italic toggle="yes">et al.</italic> compared eight polymers and found that only the cationic polymers PEI, PDMAEMA, and poly(2-(dimethylamino) ethyl methacrylate-<italic toggle="yes">co</italic>-methacrylic acid) (P(DMAEMA-<italic toggle="yes">co</italic>-MAA)) possessed an excellent ability to transfect myeloid cells and DCs. Moreover, DNA vaccines using these polymers as carriers induced an anti-HBsAg antibody response <italic toggle="yes">in vivo</italic>, 9-fold higher than naked DNA <xref rid="b0310" ref-type="bibr">[62]</xref>.</p><p id="p0135">Surface-modified cationic polymers often actively target APCs to promote the phagocytosis of DNA vaccines by APCs and activate more robust humoral and cellular immune responses. For example, Soares <italic toggle="yes">et al.</italic> synthesized PDMAEMA:P&#946;AE multimers as carriers to deliver DNA, and the multimers were modified with dextran that recognizes Dectin-1 on the APC surface. Only a nanoplatform with granular &#946;-glucan glycosylation activated the downstream signaling of APCs <xref rid="b0305" ref-type="bibr">[61]</xref>. In another study, Layek <italic toggle="yes">et al.</italic> designed mannosylated phenylalanine grafted chitosan (Man-CS-Phe) to deliver DNA encoding HBsAg. The cationic micelle increased the uptake of APCs, gene expression, and antigen presentation mediated by mannose receptors. Intradermal administration of this vaccine resulted in a solid HBsAg-specific antibody response and cytokine interferon-&#947; (IFN-&#947;) secretion in mice, which is essential for enhancing cellular immunity in HBV chronic carriers <xref rid="b0315" ref-type="bibr">[63]</xref>.</p><p id="p0140">Cationic polymers have been widely reported to act as carriers or adjuvants. Additionally, several polymers extracted and purified from natural substances demonstrated adjuvant activity to activate intrinsic and adaptive cellular immunity in HBV DNA vaccination against chronic HBV infection. Du <italic toggle="yes">et al.</italic> reported the ability of <italic toggle="yes">Astragalus</italic> polysaccharide (APS) as an adjuvant to enhance the immune effect of HBV DNA vaccine <xref rid="b0320" ref-type="bibr">[64]</xref>. The results show that APS upregulated CD40, CD80, and MHC I/II in DCs. Subsequently, the proliferation of T cells was significantly increased, especially cytotoxic T lymphocytes, which specifically clear HBV, and the expressed IFN-&#947; inhibited viral replication <xref rid="b0325" ref-type="bibr">[65]</xref>. Furthermore, the vaccine also suppressed regulatory T cells and reversed the immunosuppressed state in patients with chronic hepatitis by enhancing immune response <xref rid="b0320" ref-type="bibr">[64]</xref>, <xref rid="b0330" ref-type="bibr">[66]</xref>. Moreover, the FP-1, a novel heteropolysaccharide extracted from flaxseed hulls, has been reported to inhibit HBV antigen expression (HBsAg and HBeAg) directly and interfere with DNA replication by itself. FP-1, composed of xylose, galactose, rhamnose, galactose, arabinose, fucose, glucose, and mannose, has a triple helix conformation, which allows it to stimulate macrophages to secret nitric oxide (NO), interleukin 6 (IL-6), and IL-12 thus exerting significant immunomodulatory ability and is promising as an anti-HBV drug and an adjuvant for vaccine vector <xref rid="b0335" ref-type="bibr">[67]</xref>.</p><p id="p0145">Biomaterials-based vaccines also promote the development of hepatitis C virus (HCV) vaccines. While no licensed HCV vaccine is currently available, biomaterials based on polyphosphazene have demonstrated their ability to protect the E2 glycoprotein antigen of HCV and are adjuvant to immunization <xref rid="b0340" ref-type="bibr">[68]</xref>. The water-soluble polyphosphazene is highly susceptible to self-assembly into non-covalent complexes with the E2 antigen of HCV, and the biological and chemical structural features of macromolecule allow it to bind multiple copies of the antigen and support it in a multimeric form <xref rid="b0340" ref-type="bibr">[68]</xref>, <xref rid="b0345" ref-type="bibr">[69]</xref>. For example, Andrianov <italic toggle="yes">et al.</italic> bonded poly(di(carboxylatophenoxy)phosphazene) (PCPP) to HCV E2 antigen and retained the TLR7/8 agonist R848 on the polymer chain <xref rid="b0345" ref-type="bibr">[69]</xref>. The antigen and stimulus signals delivered by PCPP were displayed in the multimeric form, which was the main reason for inducing efficient humoral and cellular immune responses. On this basis, poly(di(carboxylatoethylphenoxy)phosphazene) (PCEP), which has subtle structural difference from PCPP, was also derived <xref rid="b0350" ref-type="bibr">[70]</xref>. Despite the difference of only two methylenes, the latter elicited more potent immune effect than the former. It has been reported that the addition of HCV E2 antigen did not affect the size of PCEP, whereas the PCPP particle size showed a dose-dependent increase with HCV E2 antigen <xref rid="b0355" ref-type="bibr">[71]</xref>. Therefore, PCEP may have a more vital ability to resist agglomeration and stabilize E2 antigen than PCPP and is a more potent immune activator.</p><p id="p0150">In summary, the current development of vaccines for hepatitis viruses is mainly for HBV and HCV, while the other virus subtypes containing A, D, and E, which lack researches, are targeted to focus on in the future. Since the clearance of hepatitis virus in patients with chronic hepatitis mainly depends on antigen-specific T cells. Therefore, biomaterials-based vaccines especially enhance immunogenicity by boosting cellular immune responses. Moreover, a new role of polymers as vaccine carriers with adjuvant effect and direct inhibition of hepatitis virus DNA replication in infected cells has been reported <xref rid="b0335" ref-type="bibr">[67]</xref>. Therefore, new properties and deep mechanisms of biomaterials-based vaccines need to be explored in the future.</p></sec><sec id="s0030"><label>2.4</label><title>AIDS</title><p id="p0155">With nearly 2 million new infection each year, HIV, the pathogen of AIDS, is one of the most severe global health challenges <xref rid="b0360" ref-type="bibr">[72]</xref>. Several HIV vaccine efficacy trials have been conducted, but only the Thai RV144 vaccine (phase III clinical trial) has shown positive results. However, the efficacy of RV144 dropped from 60% to 30% within 42 to 60&#160;months after administration, suggesting that a higher-quality HIV vaccine is necessary <xref rid="b0365" ref-type="bibr">[73]</xref>. The advance in the vaccine should focus on immunogens, adjuvants, and delivery routes to stimulate higher levels of broadly neutralizing antibodies (bNAbs) and optimize preventive vaccination against HIV.</p><p id="p0160">The main types of HIV vaccines used in existing researches include subunit vaccines, nucleic acid vaccines, and so on. Concerning subunit vaccines, Envelope glycoprotein (Env) trimer and protease cleavage sites (PCS) of HIV are target peptides with limited application due to low immunogenicity <xref rid="b0370" ref-type="bibr">[74]</xref>. To improve the immune effect of Env, Francica <italic toggle="yes">et al.</italic> designed a polyamidoamine (PAMAM)-based star nanoparticle delivery system that focused on a specific Env variable loop 3/glycan site and successfully triggered high titer of bNAbs HIV <xref rid="b0375" ref-type="bibr">[75]</xref>. Similarly, Dacoba <italic toggle="yes">et al.</italic> covalently attached PCS5 to the polysaccharide-based nanoparticle, effectively increasing the anti-PCS antibody (<xref rid="f0010" ref-type="fig">Fig. 2</xref>) <xref rid="b0380" ref-type="bibr">[76]</xref>. PCS5 is bound to CS or hyaluronic acid <italic toggle="yes">via</italic> oxime or thioether bonds. The former and the latter broke under acidic and high glutathione concentration conditions, respectively, ensuring the extracellular stability of antigenic peptide and its release within the APCs. The level of PCS5 antibody produced in mice increased with time, implying that binding to the polysaccharide significantly promoted the immune potency of antigen. However, the time points at which the highest levels of humoral immunity were elicited differed between polysaccharide polymers, suggesting that vaccine composition and mode of antigen attachment also affect vaccine immunogenicity.<fig id="f0010" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Polysaccharide nanoparticle as carrier and adjuvant of vaccine against HIV infection. A) Schematic illustration of vaccine design and <italic toggle="yes">in vivo</italic> evaluation criterion. B) PCS5 release curve in only PBS or thiol-rich PBS solution. C) Changes in antibody levels over time after intramuscular immunization with three different nanovaccines. Reproduced with permission <xref rid="b0380" ref-type="bibr">[76]</xref>. Copyright 2019, American Chemical Society. Abbreviations: Ab, antibody; APCs, antigen-presenting cells; CS, chitosan; DS, dextran sulfate; GSH, glutathione; HA, hyaluronic acid; HIV, human immunodeficiency virus; PBS, phosphate buffered saline; PCS5, protease cleavage site 5; pIC, polyinosinic:polycytidylic acid (poly(I:C)).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="lk00010" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0165">Moreover, adding adjuvants significantly aid the induction of bNAbs in subunit vaccines. TLR agonists are widely used as vaccine adjuvants but have poor pharmacokinetics and significant side effects <xref rid="b0385" ref-type="bibr">[77]</xref>. In a recent study, TLR7/8 agonists were covalently bound to hyperbranched polymers. Th1 cell immune response was significantly enhanced when the polymers interacted with HIV Env gp120, indicating that the complex formed by TLR, glycoprotein gp120, and polymers improve the effectiveness of a single component <xref rid="b0390" ref-type="bibr">[78]</xref>. Furthermore, the innovations in preparation and administration will also bring advances for subunit vaccines. For instance, Boopathy <italic toggle="yes">et al.</italic> designed the poly(acrylic acid) (PAA)-supporting silk fibroin protein MN encapsulating HIV Env immunogen <xref rid="b0395" ref-type="bibr">[79]</xref>. Compared to intradermal injection, MN implantation induced a 300-fold increase in serum IgG titers and a 16-fold increase in bone marrow plasma cells, significantly improving vaccine immunization efficiency.</p><p id="p0170">DNA and RNA have also been developed for HIV nucleic acid vaccines. As mentioned above, achievement of stable and sustained delivery is a significant challenge for nucleic acid vaccines. Lu <italic toggle="yes">et al.</italic> prepared a hybrid two-particle delivery system by introducing polyplex of poly(ethylene glycol)-<italic toggle="yes">graft</italic>-poly(ethylene imine) (PEG-<italic toggle="yes">g</italic>-PEI) and HIV DNA into PLGA microsphere <xref rid="b0400" ref-type="bibr">[80]</xref>. The delivery system significantly improved DNA stability and intracellular release dynamics. Furthermore, long-term sustained immunization is essential in addition to stability, especially for HIV-1 patients. Compared to HIV-2, HIV-1 is a more virulent class of HIV, and patients with HIV-1 will have weaker persistent T cell immunity <xref rid="b0405" ref-type="bibr">[81]</xref>. Enhancing the T cell response to the most vulnerable functional conserved regions of HIV-1 could be the key to success, and tHIVconsvX immunogens help do this <xref rid="b0410" ref-type="bibr">[82]</xref>. Moyo <italic toggle="yes">et al.</italic> synthesized a PEI-saRNA platform to deliver tHIVconsvX <xref rid="b0415" ref-type="bibr">[83]</xref>. The platform induced a wide range of specific multifunctional CD8<sup>+</sup> and CD4<sup>+</sup> T cells at a high level for at least 22&#160;weeks, indicating the immunological effect of this vaccine.</p><p id="p0175">Briefly, the existing studies mainly focused on subunit vaccines and nucleic acid vaccines. Although there are clinical studies of HIV vaccines, such as PrepVacc, HVTN 706/HPX3002, and HVTN 705/HPX2008, they have not been commercialized <xref rid="b0420" ref-type="bibr">[84]</xref>. The most important reason for this is the high genetic diversity of HIV driven by Env. In addition, most conventional immunogen delivery systems are incapable of inducing effective and durable immunity to HIV. Biomaterials have emerged as an asset in addressing these dilemmas. In the future, approaches targeting stimulation of the production of bNAb to B cell precursors, novel vaccine delivery systems, and combination vaccines will be the focuses for biomaterials-based HIV vaccines.</p></sec><sec id="s0035"><label>2.5</label><title>Other viruses-associated diseases</title><p id="p0180">In addition to the viruses mentioned above, other viruses also cause severe infectious diseases in recent years, including the human papillomavirus (HPV), Ebola virus, dengue fever, Zika virus, <italic toggle="yes">etc.</italic> Some reviews have described the applications of biomaterials in these viruses <xref rid="b0425" ref-type="bibr">[85]</xref>, <xref rid="b0430" ref-type="bibr">[86]</xref>, <xref rid="b0435" ref-type="bibr">[87]</xref>. In this section, we focus on the limitations of existing vaccines against these viruses-associated diseases and the efforts made by biomaterials to overcome the obstacles.</p><p id="p0185">HPV is the most common pathogen of sexual diseases in the United States, causing various anal, penile, cervical cancer, and so forth <xref rid="b0440" ref-type="bibr">[88]</xref>. Three HPV vaccines have been approved to prevent the most dangerous strains of HPV, with the nine-valent Gardasil-9 containing Alum preventing 90% of HPV-related cancers yearly <xref rid="b0445" ref-type="bibr">[89]</xref>. However, HPV vaccination rates remain suboptimal due to the need for three injections to maintain adequate immunogenicity and the stress of cold chain transport <xref rid="b0450" ref-type="bibr">[90]</xref>. To solve the problem, Shao <italic toggle="yes">et al.</italic> designed an implanted PLGA MN patch to transport HPV-Q&#946; viral-like particle (VLP) vaccine <xref rid="b0455" ref-type="bibr">[91]</xref>. The high-temperature melt processing enabled single-dose inoculation of HPV-Q&#946; particle, sustained immune response, and relief of cold-chain requirement.</p><p id="p0190">Another way to improve vaccination efficiency is to replace the Alum adjuvant in the current HPV vaccine. Recently, polyphosphazene macromolecular adjuvants, such as PCEP and poly(di(carboxylatomethylphenoxy)phosphazene) (PCMP), have been found to form supramolecular self-assemblies with the HPV16L1-16L2 virus-like particle (RG1-VLP) vaccine for HPV, which showed strong humoral immunity against HPV infection <xref rid="b0460" ref-type="bibr">[92]</xref>, <xref rid="b0465" ref-type="bibr">[93]</xref>. Valencia <italic toggle="yes">et al.</italic> reported that RG1-VLP vaccine doses adjuvanted by PCEP could be reduced by 75%, and the level of produced antibody was higher than that of a vaccine with the VLP/Alum adjuvant alhydrogel <xref rid="b0460" ref-type="bibr">[92]</xref>. Therefore, biomaterials-based adjuvants are the preferred choice of HPV vaccine adjuvants.</p><p id="p0195">Ebola fever, caused by the Ebola virus, is one of the most dangerous infectious diseases known to man <xref rid="b0470" ref-type="bibr">[94]</xref>. Recent studies have shown that vaccines against Ebola require effective stimulation of T cell immune responses, specifically CD8<sup>+</sup> T cells <xref rid="b0475" ref-type="bibr">[95]</xref>. Karpenko <italic toggle="yes">et al.</italic> constructed a plasmid encoding T cell immunogens to generate artificial T cell immunogens in transfected cells for specific responses to CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes <xref rid="b0480" ref-type="bibr">[96]</xref>. Assisted by PAMAM dendrimer, the DNA vaccines induced significant T cell response in mice. However, the DNA delivery efficiency of vaccine is related to the size and surface charge of dendrimer, and the exact mechanism is unknown and needs further exploration. Further, vaccine candidates that induce T cell immune responses for a relatively short time after vaccination are still under development, which could be a possible direction for future researches on biomaterials-based anti-Ebola vaccines.</p><p id="p0200">Dengue fever is an infectious disease caused by the dengue virus transmitted by insect-borne bites <xref rid="b0485" ref-type="bibr">[97]</xref>. It is caused by any of the four serotypes of dengue virus, and systems in infected individuals range from fever to severe dengue hemorrhagic fever and shock syndrome that threaten human health <xref rid="b0490" ref-type="bibr">[98]</xref>. Currently, the vaccine Dengvaxia is approved in Mexico, Brazil, and the Philippines for use in people aged 9&#8211;45&#160;years <xref rid="b0490" ref-type="bibr">[98]</xref>. However, in a cohort study of children vaccinated in the Philippines, the vaccine was found to protect against severe dengue fever in seropositive individuals but increased the risk of untreated severe dengue infection and hospitalization <xref rid="b0495" ref-type="bibr">[99]</xref>. Therefore, the development of a safer and more effective vaccine is imminent.</p><p id="p0205">By mimicking the natural transmission mode of dengue virus, vaccines by the transdermal route have attracted significant interest. There is data supporting the ability of percutaneous inoculation to activate Langerhans cells and dermal DCs that produce more robust immune responses than deeper subcutaneous vaccination <xref rid="b0500" ref-type="bibr">[100]</xref>. In a recent study, a subunit vaccine composed of a dengue virus antigen and two adjuvants was made into a multi-layer MN consisting of P&#946;AE, PAA, and poly(<italic toggle="yes">O</italic>-nitrobenzylmethacrylate-<italic toggle="yes">co</italic>-(hydroxyethyl methacrylate)-<italic toggle="yes">co</italic>-(poly(ethylene glycol) methacrylate)) for percutaneous injection <xref rid="b0505" ref-type="bibr">[101]</xref>. In an <italic toggle="yes">in vitro</italic> human skin model and <italic toggle="yes">in vivo</italic> mice model, the MN vaccine had been demonstrated to achieve sustained and co-release of adjuvant and antigen to APCs for up to two weeks. The long-lasting immune activation effect in the context of biomaterial involvement will drive the development of vaccines against dengue. Such vaccines designed to exploit the infection pathway and characteristics of the virus will be more expected.</p><p id="p0210">Zika virus is an arbovirus belonging to the Flavivirus genus of Flaviviridae family <xref rid="b0510" ref-type="bibr">[102]</xref>. Because of the association with neurological disorders and fetal abnormalities, vaccine development is critical for pregnant women and travelers in endemic areas. Immune adjuvants are usually required to enhance the immunogenicity of vaccines, and traditional Alum adjuvants that induce Th1/2 responses in humans have been successfully used to prepare viral vaccines in humans. However, they may increase the risk of neurotoxicity and immune diseases, leading to side effects <xref rid="b0515" ref-type="bibr">[103]</xref>. In this context, Wu <italic toggle="yes">et al.</italic> encapsulated inactivated Zika virus in a nanocomplex consisting of CS and &#947;-poly(glutamic acid) (&#947;-PGA) by the electrokinetic method <xref rid="b0520" ref-type="bibr">[104]</xref>. The nanocomplex, acting as an immune adjuvant, successfully induced anti-Zika virus IgG1 and IgG2a antibodies with balanced Th1/2 responses in mice. This result demonstrates that biomaterials with simple composition and inherent immune adjuvant properties extend the currently limited number of vaccine adjuvants to improve immunogenicity.</p><p id="p0215">The above types of infectious diseases are still prevalent in some places, causing damage to people and property. However, the development of vaccines for these types of viruses, including HPV, Ebola virus, dengue fever, and Zika virus, is still limited and needs to be explored in depth. Above all, new adjuvants other than conventional Alum adjuvants that can be delivered together with the vaccine must be found. Furthermore, the vaccine design concept needs to incorporate the characteristics of virus itself, including the chemical structure, the route of transmission, and the mode of immune response of the organism.</p></sec></sec><sec id="s0040"><label>3</label><title>Immunologically effective biomaterials-enhanced vaccines against bacterial infection</title><p id="p0220">Different bacteria cause diseases with similar clinical manifestations, but there is a great deal of specificity between genera. Different subtypes of antigens are also present in the same genus, leading to complexity and difficulty in vaccine design. Immunogenic biomaterials-adjuvanted vaccines deliver multiple subantigenic units simultaneously, improving the immunogenicity of antimicrobial vaccines. This chapter will focus on the value of polymers-based vaccines in preventing respiratory and intestinal infectious diseases caused by bacteria (<xref rid="t0010" ref-type="table">Table 2</xref>).<table-wrap position="float" id="t0010" orientation="portrait"><label>Table 2</label><caption><p>Immunologically effective biomaterials-enhanced vaccines against bacterial infection.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Pathogenic virus</th><th colspan="1" rowspan="1">Vaccine type</th><th colspan="1" rowspan="1">Antigen</th><th colspan="1" rowspan="1">Polymer</th><th colspan="1" rowspan="1">Delivery system</th><th colspan="1" rowspan="1">Adjuvant</th><th colspan="1" rowspan="1">Route</th><th colspan="1" rowspan="1">Result</th><th colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td rowspan="4" colspan="1"><italic toggle="yes">S. pneumoniae</italic></td><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">PsaA</td><td colspan="1" rowspan="1">CS</td><td colspan="1" rowspan="1">CS-PsaA nanocapsule</td><td colspan="1" rowspan="1">&#8212;</td><td colspan="1" rowspan="1"><italic toggle="yes">i.n.</italic></td><td colspan="1" rowspan="1">The nanocapsule effectively delivered antigen with ideal mucosal adhesion, stability, and immune effect.</td><td colspan="1" rowspan="1"><xref rid="b0540" ref-type="bibr">[108]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">PspA</td><td colspan="1" rowspan="1">cCHP</td><td colspan="1" rowspan="1">cCHP-PspA nanogel</td><td colspan="1" rowspan="1">&#8212;</td><td colspan="1" rowspan="1"><italic toggle="yes">i.n.</italic></td><td colspan="1" rowspan="1">The vaccine significantly induced IgG and C3 deposition in macaques.</td><td colspan="1" rowspan="1"><xref rid="b0550" ref-type="bibr">[110]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">PspA</td><td colspan="1" rowspan="1">cCHP</td><td colspan="1" rowspan="1">cCHP-PspA nanogel</td><td colspan="1" rowspan="1">&#8212;</td><td colspan="1" rowspan="1"><italic toggle="yes">i.n.</italic></td><td colspan="1" rowspan="1">The immune responses induced by nanogel in non-human primates were mediated by Th2 and Th17, and the nanogel was not deposited in the brain.</td><td colspan="1" rowspan="1"><xref rid="b0555" ref-type="bibr">[111]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">PspA</td><td colspan="1" rowspan="1">P&#946;AE</td><td colspan="1" rowspan="1">P&#946;AE and <italic toggle="yes">E. coli</italic> hybrid</td><td colspan="1" rowspan="1"><italic toggle="yes">E. coli</italic> with natural adjuvant properties</td><td colspan="1" rowspan="1"><italic toggle="yes">i.p.</italic>/<italic toggle="yes">s.c.</italic>/<italic toggle="yes">i.n.</italic></td><td colspan="1" rowspan="1">Hybrid biomaterial vector provided opportunity for &#8220;<italic toggle="yes">in situ</italic>&#8221; antigen production in APCs.</td><td colspan="1" rowspan="1"><xref rid="b0105" ref-type="bibr">[21]</xref></td></tr><tr><td rowspan="5" colspan="1"><italic toggle="yes">Mtb</italic></td><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">HspX (Rv2031c), EsxV (Rv19c), and PPE44 (Rv2770c)</td><td colspan="1" rowspan="1">CS or TMC</td><td colspan="1" rowspan="1">CS- or TMC-coated PLGA nanoparticle</td><td colspan="1" rowspan="1">CS- or TMC</td><td colspan="1" rowspan="1"><italic toggle="yes">i.n.</italic> or <italic toggle="yes">s.c.</italic></td><td colspan="1" rowspan="1">Subcutaneous administration elicited higher cellular immunity compared to nasal administration and TMC-coated PLGA nanoparticle enhanced Th1 and mucosal immunity more effectively than CS.</td><td colspan="1" rowspan="1"><xref rid="b0575" ref-type="bibr">[115]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">10&#160;kDa culture filtrate protein and ESAT-6</td><td colspan="1" rowspan="1">CS or polyarginine</td><td colspan="1" rowspan="1">CS:Ag, INU:PArg:Ag, or INU:Ag:PArg nanocapsule</td><td colspan="1" rowspan="1">TLR7/8 agonist imiquimod</td><td colspan="1" rowspan="1"><italic toggle="yes">i.n.</italic></td><td colspan="1" rowspan="1">Only vaccine containing INU: PArg: Ag induced sufficient IgA.</td><td colspan="1" rowspan="1"><xref rid="b0585" ref-type="bibr">[117]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">H4 and H8 fusion antigen</td><td colspan="1" rowspan="1">Polyester</td><td colspan="1" rowspan="1">Polyester-particle self-assembly in the presence of (<italic toggle="yes">R</italic>)-hydroxybutyryl-CoA</td><td colspan="1" rowspan="1">&#8212;</td><td colspan="1" rowspan="1"><italic toggle="yes">s.c.</italic></td><td colspan="1" rowspan="1">The polyester-particle vaccine induced relatively strong production of IFN-&#947; and IL-17A cytokines.</td><td colspan="1" rowspan="1"><xref rid="b0595" ref-type="bibr">[119]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">H4 and H8 fusion antigen</td><td colspan="1" rowspan="1">Polyester</td><td colspan="1" rowspan="1">Polyester<break/>nanoparticle-H28 and H28 nanoparticle</td><td colspan="1" rowspan="1">&#8212;</td><td colspan="1" rowspan="1"><italic toggle="yes">s.c.</italic></td><td colspan="1" rowspan="1">Polyester nanoparticle of <italic toggle="yes">Bifidobacterium bovis</italic> antigen-fused H4 induced protective immunity in the lung at a level similar to that of BCG.</td><td colspan="1" rowspan="1"><xref rid="b0600" ref-type="bibr">[120]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">ESAT-6 and antigen 85A</td><td colspan="1" rowspan="1">PHA</td><td colspan="1" rowspan="1">PHA bio-bead produced by <italic toggle="yes">Mycobacterium discoideum</italic></td><td colspan="1" rowspan="1">&#8212;</td><td colspan="1" rowspan="1"><italic toggle="yes">s.c.</italic></td><td colspan="1" rowspan="1">The vaccine enabled the immobilization of specific antigens onto the surface of PHA bio-bead to prevent <italic toggle="yes">Mtb.</italic></td><td colspan="1" rowspan="1"><xref rid="b0605" ref-type="bibr">[121]</xref></td></tr><tr><td rowspan="4" colspan="1"><italic toggle="yes">E. coli</italic></td><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">rEIT (EspA, Intimin, and Tir)</td><td colspan="1" rowspan="1">CS</td><td colspan="1" rowspan="1">CS nanoparticle</td><td colspan="1" rowspan="1">&#8212;</td><td colspan="1" rowspan="1">Oral</td><td colspan="1" rowspan="1">Adhesion of <italic toggle="yes">E. coli</italic> O157: H7 to intestinal epithelial cells decreased by loading CS with rEIT antigen.</td><td colspan="1" rowspan="1"><xref rid="b0625" ref-type="bibr">[125]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">F4 antigen</td><td colspan="1" rowspan="1">CS</td><td colspan="1" rowspan="1">Eudragit L100 modified porous CS nanoparticle</td><td colspan="1" rowspan="1">&#8212;</td><td colspan="1" rowspan="1">Oral</td><td colspan="1" rowspan="1">Eudragit L100 modified oral porous nanoparticle reduced the excretion of ETEC<italic toggle="yes">.</italic></td><td colspan="1" rowspan="1"><xref rid="b0630" ref-type="bibr">[126]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">CfaB, CstH, CotA, and LTB</td><td colspan="1" rowspan="1">PLGA</td><td colspan="1" rowspan="1">PLGA nanoparticle</td><td colspan="1" rowspan="1">&#8212;</td><td colspan="1" rowspan="1">Oral</td><td colspan="1" rowspan="1">The vaccine inhibited the binding of enterotoxin to GM1-gangliosides and neutralized the effects of LTB toxin on effusions in the loop of ileum.</td><td colspan="1" rowspan="1"><xref rid="b0635" ref-type="bibr">[127]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">LTB, STXB, and CTXB</td><td colspan="1" rowspan="1">CS</td><td colspan="1" rowspan="1">CS nanoparticle</td><td colspan="1" rowspan="1">&#8212;<break/></td><td colspan="1" rowspan="1">Oral</td><td colspan="1" rowspan="1">The nanovaccine with all three antigens prevented from ETEC and EHEC attacking.</td><td colspan="1" rowspan="1"><xref rid="b0645" ref-type="bibr">[129]</xref></td></tr><tr><td rowspan="5" colspan="1"><italic toggle="yes">Shigella</italic></td><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">MxiH antigen</td><td colspan="1" rowspan="1">CS</td><td colspan="1" rowspan="1">CS nanoparticle</td><td colspan="1" rowspan="1">&#8212;<break/></td><td colspan="1" rowspan="1"><italic toggle="yes">i.n.</italic></td><td colspan="1" rowspan="1">CS vaccine coated with MxiH antigen stimulated B cells and increased IgG and IgA in nasal epithelium mucosa.</td><td colspan="1" rowspan="1"><xref rid="b0655" ref-type="bibr">[131]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1">OMV antigen complex</td><td colspan="1" rowspan="1">Gantrez&#174; AN119</td><td colspan="1" rowspan="1">Thermo-sensitive hydrogel consisting of polymer Gantrez&#174; AN119 and surfactant Pluronic F127</td><td colspan="1" rowspan="1">&#8212;<break/></td><td colspan="1" rowspan="1"><italic toggle="yes">i.n.</italic></td><td colspan="1" rowspan="1">Delivery of thermo-sensitive hydrogel prolonged the residence time of OMV antigen in nasal cavity.</td><td colspan="1" rowspan="1"><xref rid="b0670" ref-type="bibr">[134]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1"><italic toggle="yes">N</italic>-terminal region of IpaD antigen</td><td colspan="1" rowspan="1">CS</td><td colspan="1" rowspan="1"><italic toggle="yes">O</italic>-metylated free TMC nanoparticle</td><td colspan="1" rowspan="1">&#8212;<break/></td><td colspan="1" rowspan="1">Oral</td><td colspan="1" rowspan="1">The TMC-coated antigens significantly enhanced antigen-specific IgG and IgA in <italic toggle="yes">Shigella flexneri</italic>-infected guinea pigs compared to naked antigens.</td><td colspan="1" rowspan="1"><xref rid="b0675" ref-type="bibr">[135]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1"><italic toggle="yes">O</italic>-<break/>polysaccharide</td><td colspan="1" rowspan="1">Polysaccharide</td><td colspan="1" rowspan="1">Self-assembled<break/>proteinaceous<break/>nanoparticle</td><td colspan="1" rowspan="1">&#8212;</td><td colspan="1" rowspan="1"><italic toggle="yes">s.c.</italic></td><td colspan="1" rowspan="1">The Nano-B5 platform can be combined with different modular components and antigens to protect the continued survival of all animals.</td><td colspan="1" rowspan="1"><xref rid="b0090" ref-type="bibr">[18]</xref></td></tr><tr><td colspan="1" rowspan="1">Subunit vaccine</td><td colspan="1" rowspan="1"><italic toggle="yes">O</italic>-<break/>polysaccharide</td><td colspan="1" rowspan="1">Polysaccharide</td><td colspan="1" rowspan="1">Polysaccharide-nanoconjugate VLP</td><td colspan="1" rowspan="1">&#8212;</td><td colspan="1" rowspan="1"><italic toggle="yes">s.c.</italic></td><td colspan="1" rowspan="1">The <italic toggle="yes">O</italic>-polysaccharide obtained from <italic toggle="yes">Shigella flexneri 2a</italic> can be bound to the surface of VLP to prevent <italic toggle="yes">Shigella</italic> infection.</td><td colspan="1" rowspan="1"><xref rid="b0685" ref-type="bibr">[137]</xref></td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: Ag, antigen; APCs, antigen-presenting cells; BCG, Bacille Calmette-Gu&#233;rin; cCHP, cationic cholesteryl pullulan; CfaB, complement factor B; CoA, coenzyme A; CotA, coat protein A; CS, chitosan; CTXB, cholera toxin B subunit; <italic toggle="yes">E. coli</italic>, <italic toggle="yes">Escherichia coli</italic>; EHEC, enterohemorrhagic&#160;<italic toggle="yes">E. coli</italic>; ESAT-6, early secreted antigenic target of 6 kD; EspA, <italic toggle="yes">E. coli</italic>-secreted proteins A; EsxV, mycobacterium tuberculosis antigen Rv2031c; ETEC, enterotoxigenic <italic toggle="yes">E. coli</italic>; GM1, monosialotetrahexosylganglioside; HspX, &#945;-crystallin chaperone protein homologue; IFN-&#947;, interferon-&#947;; IgA, immunoglobulin A; IgG, immunoglobulin G; IL, interleukin; <italic toggle="yes">i.n.</italic>, intranasal injection; INU, inulin; <italic toggle="yes">i.p.</italic>, intraperitoneal injection; IpaD, invasion plasmid antigen D; LTB, Heat-labile B subunit; <italic toggle="yes">Mtb</italic>,&#160;<italic toggle="yes">Mycobacterium tuberculosis</italic>; OMV, outer membrane vesicles; PArg, polyarginine; PHA, polyhydroxyalkanoate; PLGA, poly(lactic-<italic toggle="yes">co</italic>-glycolic acid); PPE44, mycobacterium tuberculosis antigen Rv2770c; PsaA, pneumococcal surface acrylate A; PspA, pneumococcal surface protein A; P&#946;AE, poly(&#946;-amino ester); rEIT, EspA, Intimin, and Tir; <italic toggle="yes">S. pneumoniae</italic>, <italic toggle="yes">Streptococcus pneumoniae</italic>; <italic toggle="yes">s.c.</italic>, subcutaneous injection; STXB, Shiga toxin B subunit; Th, helper T cell; Tir, translocated intimin receptor; TLR, toll-like receptor; TMC, <italic toggle="yes">N</italic>-trimethyl chitosan; VLP, viral-like particle.</p></fn></table-wrap-foot></table-wrap></p><sec id="s0045"><label>3.1</label><title>Respiratory infectious diseases</title><p id="p0225">Respiratory diseases caused by bacteriologic pathogens also produce serious health problems, and the main victim groups include children and the elderly and immunodeficient populations. Relevant studies of vaccines against such pathogens have been developed for several years, such as the 23-valent polysaccharide conjugate vaccine against pneumococcal infection and Bacille Calmette-Gu&#233;rin (BCG) vaccine against TB infection <xref rid="b0525" ref-type="bibr">[105]</xref>, <xref rid="b0530" ref-type="bibr">[106]</xref>. However, these vaccines are administered by a single intramuscular injection and provide protective immunity against only several serotypes. Since these bacteria are present in the mucous membrane of respiratory tract through fixed values, vaccines need to be developed to elicit a broad immune response and produce mucosal and systemic protection. Biomaterials-based vaccines have been used to deliver multiple subtypes of antigens and optimize the administration mode to compensate for the above limitations. This section will focus on polymer-related vaccines to prevent <italic toggle="yes">S. pneumoniae</italic> and <italic toggle="yes">Mtb</italic>.</p><p id="p0230"><italic toggle="yes">S. pneumoniae</italic>, a gram-positive bacterium, often colonizes the upper respiratory tract of humans, causing pneumonia and sepsis. There are a variety of proteins and capsular polysaccharides on the cell surface of <italic toggle="yes">S. pneumoniae</italic>, some of which are expressed on all serotypes and are, therefore, candidate antigens for subunit vaccines, such as pneumococcal surface protein A (PspA) and pneumococcal surface acrylate A (PsaA) <xref rid="b0535" ref-type="bibr">[107]</xref>. Many vaccine delivery systems loading these widely expressed protein antigens have been developed to achieve universal prevention of pneumococcal disease <xref rid="b0540" ref-type="bibr">[108]</xref>, <xref rid="b0545" ref-type="bibr">[109]</xref>, <xref rid="b0550" ref-type="bibr">[110]</xref>, <xref rid="b0555" ref-type="bibr">[111]</xref>. For example, Robla <italic toggle="yes">et al.</italic> designed the thiol-maleimide-conjugated CS nanocapsule loaded with PsaA <xref rid="b0540" ref-type="bibr">[108]</xref>. The covalent polymer-protein binding in the nanocapsule resulted in a 3-fold increase in PsaA binding. Meanwhile, the epithelial adhesion property of CS enabled the nanocapsule to present PsaA adequately to APCs in the nasal mucosa to activate CD4<sup>+</sup> and CD8<sup>+</sup> T cells, indicating that nanocapsule effectively delivered PsaA with outstanding mucosal adhesion, stability, and immune effect. It is worth noting that using maleimide as a cross-linking agent for thiols requires careful consideration. Due to the immunogenicity of maleimide, it may inhibit the immune response to the linker ligand <xref rid="b0560" ref-type="bibr">[112]</xref>.</p><p id="p0235">However, the most critical vaccine regimen to prevent <italic toggle="yes">S. pneumoniae</italic> transmission is to produce specific IgG and IgA antibodies to block the infection and epithelial fixation of the pathogen, respectively. In this regard, PspA seems to have a significant advantage over PsaA <xref rid="b0565" ref-type="bibr">[113]</xref>. Cross-reactive neutralizing immune effects have been reported to be induced by nanogel made of cationic cholesterol branched-chain starch piggybacked on PspA as an adjuvant-free vaccine <xref rid="b0545" ref-type="bibr">[109]</xref>. Hiroshi Kiyono and co-workers tried to validate the effect, mechanism, and safety of cationic cholesteryl pullulan (cCHP) nanogel vaccine <xref rid="b0545" ref-type="bibr">[109]</xref>, <xref rid="b0550" ref-type="bibr">[110]</xref>, <xref rid="b0555" ref-type="bibr">[111]</xref>. The adjuvant-free vaccine induced the same IgG levels as Alum adjuvant in mice intranasally and induced PspA-specific IgA <xref rid="b0550" ref-type="bibr">[110]</xref>. The immune effect mainly depended on the immune response mediated by Th2 and Th17. Furthermore, as proved by nuclear magnetic resonance, the vaccines were not deposited in the olfactory bulb and brain of macaques, indicating their safety <xref rid="b0555" ref-type="bibr">[111]</xref>. Thus, the development of adjuvant-free cCHP nanogel vaccine is a safe and effective strategy expected to prevent human pneumonia transmission.</p><p id="p0240">While direct delivery of PspA promotes the immunogenicity of original subunit vaccine, it would be more attractive to design vectors that deliver a broad range of antigenic forms and enhance the immune response in multiple dimensions. A unique strategy is to deliver PspA by hybrid biological-biomaterial vectors. For example, Li <italic toggle="yes">et al.</italic> designed a hybrid vaccine utilizing a non-pathogenic <italic toggle="yes">E. coli</italic> with natural adjuvant effects as the biological core of vector and a mannosylated P&#946;AE coating as the biomaterial component <xref rid="b0105" ref-type="bibr">[21]</xref>. Active targeting and uptake of APCs have provided the potential for intracellular antigenic integration and release of <italic toggle="yes">E. coli</italic> in the APCs. Interestingly, each component of the hybrid vector promotes the immune response, and the vector adjuvant induced higher IgG and IgA levels than the Alum adjuvant at a 20-fold lower PspA dose. Even the vaccine produced neutralizing antibodies against 11 strains of <italic toggle="yes">S. pneumoniae</italic>, inducing a broad spectrum of anti-pneumococcal immunity. Using <italic toggle="yes">E. coli</italic> as a core, a common tool in molecular biology, hybrid biological biomaterials offer new ideas for smart vaccines produced with built-in antigens. Strategies and combinations of biomaterials and biological components that complement each other and increase the immunogenic effects will deserve more in-depth explorations in the future.</p><p id="p0245">TB, mainly caused by <italic toggle="yes">Mtb</italic> and <italic toggle="yes">Mycobacterium bovis</italic>, is the ninth leading cause of death worldwide <xref rid="b0030" ref-type="bibr">[6]</xref>. There are currently two main types of vaccine candidates to prevent TB. One is the mycobacterial whole-cell-derived vaccine, represented by BCG, the only vaccine approved to date to prevent TB in infants <xref rid="b0570" ref-type="bibr">[114]</xref>. Another is a subunit vaccine that selects a limited number of antigens, such as the fusion antigen of H4 and H28 <xref rid="b0570" ref-type="bibr">[114]</xref>. Subunit vaccines are easier to be promoted because of their diverse antigen composition, effectiveness in combination with adjuvants, and high safety. Like subunit vaccines against other pathogens, subunit vaccines that prevent TB require integration with advanced delivery platforms to improve their poor immunogenicity.</p><p id="p0250">The conventional strategy is for the biomaterials to act as adjuvants or carry an adjuvant to enhance the immunogenicity of subunit vaccines. Degradable and biosafe polymers, such as PLGA and CS, are highly recommended among such carriers. Zare <italic toggle="yes">et al.</italic> designed a PLGA nanosphere carrier modified with cationic CS or <italic toggle="yes">N</italic>-trimethyl chitosan (TMC) to transport triple-fused antigens for TB vaccines, eliciting excellent cytoprotective and mucosal immunity <xref rid="b0575" ref-type="bibr">[115]</xref>. In addition to its inherent immune-activating properties, CS has excellent mucosal adsorption capacity to facilitate the action of delivered antigens across the mucosal barrier <xref rid="b0580" ref-type="bibr">[116]</xref>. In contrast, tuberculosis is transmitted by inhaling <italic toggle="yes">Mtb</italic>-containing aerosols, making CS an excellent intranasal vaccine carrier and immune adjuvant. Nevertheless, in another study, Diego-Gonz&#225;lez <italic toggle="yes">et al.</italic> compared CS and inulin/polyarginine as nanocapsule shell to deliver the TLR7/8 agonist imiquimod and the ESAT-6-CFP-10 fusion antigen that elicited mucosal immunity <xref rid="b0585" ref-type="bibr">[117]</xref>. Despite the better immune activation property of CS-based vaccine <italic toggle="yes">in vitro</italic>, <italic toggle="yes">in vivo</italic> experiments confirmed that specific sIgA antibody was induced only when the antigen was modified on the surface of inulin/polyarginine polymer. This phenomenon may be because upon binding to the antigen, the latter has a stronger positive charge and is more favorable to interact with negatively charged epithelial mucins <xref rid="b0590" ref-type="bibr">[118]</xref>. This also indicates that the composition of polymer and the location of antigen significantly affect the immune effect of vaccine.</p><p id="p0255">Another strategy is the surface immobilization and presentation of mycobacterial antigen fusions by particle delivery systems made of biomaterials and biological components. One of the particle systems of interest is the polyhydroxyalkanoate (PHA) bio-bead class. This naturally occurring biopolyester self-assembles to form the hydrophobic core of particles. The researchers combined this property with bioengineering of the delivery of proteins needed on the surface of polyester particles as a multi-antigen delivery library for extended <italic toggle="yes">Mtb</italic>
<xref rid="b0595" ref-type="bibr">[119]</xref>, <xref rid="b0600" ref-type="bibr">[120]</xref>, <xref rid="b0605" ref-type="bibr">[121]</xref>. For example, Chen <italic toggle="yes">et al.</italic> transformed plasmids encoding PHA synthase (a key enzyme for polyester particle biosynthesis) and TB antigen (H4/H28) into bioengineering of <italic toggle="yes">ClearColi</italic> BL21 (DE3) for polyester particle production <xref rid="b0595" ref-type="bibr">[119]</xref>. In contrast to the soluble H4/H28 vaccine, the surface antigen of polyester particle vaccine triggered specific CD4<sup>+</sup> T cell effect, demonstrating IFN-&#947;-stimulated secretion levels of up to 20,000&#160;pg&#160;mL<sup>&#8211;</sup><sup>1</sup>, an essential indicator of the efficacy of anti-<italic toggle="yes">Mtb</italic> vaccine <xref rid="b0570" ref-type="bibr">[114]</xref>, <xref rid="b0595" ref-type="bibr">[119]</xref>. Furthermore, the H4/H28 surface antigen vaccine delivered by polyester particle also induced a long-lasting memory T cell immune response, with Th1 cytokine secretion still detectable up to 12&#160;weeks after the last vaccination <xref rid="b0600" ref-type="bibr">[120]</xref>. A further strategy is to replace DE3 with <italic toggle="yes">Mycobacterium</italic> to produce PHA bio-beads to obtain diverse subunit vaccine antigens that achieve immunogenicity comparable to that of attenuated or inactivated vaccines <xref rid="b0605" ref-type="bibr">[121]</xref>. Nevertheless, the efficacy of such vaccines against TB is currently unproven and needs further exploration.</p><p id="p0260">In conclusion, the bacteria invade the organism and first fixate on the respiratory mucosa, so the design of vaccine firstly requires the induction of secretory IgA and serum IgG antibodies. Second, this mode of pathogen invasion makes nasal administration unique. The vaccine vectors need immunogenicity and mucosal adhesion properties in this route. They are expected to break the mucosal barrier, protect the antigens from nasal enzymatic degradation, and enhance vaccine delivery to the nasal lymphoid tissue to promote an immunological effect of vaccines.</p></sec><sec id="s0050"><label>3.2</label><title>Intestinal infectious diseases</title><p id="p0265">Intestinal diseases remain the leading cause of morbidity and mortality in infants and young children in developing countries. In addition to viral pathogens, bacterial pathogens are the leading cause of intestinal infection. The bacteria present in the gastrointestinal tract of humans mainly belong to the Enterobacteriaceae family, most of which are the normal intestinal tract flora. When the state of host organism changes, bacteria with pathogenic effects on humans, such as pathogenic <italic toggle="yes">E. coli</italic> and <italic toggle="yes">Shigella</italic>, cause intestinal infection in the body, manifested as changes in the performance of feces, diarrhea, intestinal bleeding, etc., and in severe cases, even life-threatening <xref rid="b0610" ref-type="bibr">[122]</xref>. Unfortunately, no effective vaccine protects humans from gastrointestinal infection <xref rid="b0615" ref-type="bibr">[123]</xref>. The main obstacles are considerable genus specificity of the pathogenic bacteria, the weak immunogenicity of antigens, and the limitations of gastrointestinal mode of administration. Therefore, polymer vaccines can be designed to address these weaknesses, thus reducing the fixation and virulence of pathogenic bacteria in the gastrointestinal tract.</p><p id="p0270">There are five subtypes of pathogenic <italic toggle="yes">E. coli</italic> of which the most susceptible to the disease are enterotoxigenic <italic toggle="yes">E. coli</italic> (ETEC) and enterohemorrhagic <italic toggle="yes">E. coli</italic> (EHEC). These bacteria first colonize the intestinal epithelial cells through bacterial hairs and release large amounts of toxins that impair cell function. The former mainly causes diarrhea in humans, while the latter has caused global outbreaks of hemorrhagic colitis and hemolytic uremic syndrome <xref rid="b0620" ref-type="bibr">[124]</xref>. Therefore, blocking the colonization of intestinal tract by bacterial hairs has become a primary goal in producing pathogenic <italic toggle="yes">E. coli</italic> vaccines.</p><p id="p0275">Earlier, Khanifar <italic toggle="yes">et al.</italic> used CS to piggyback on the colonization factor of EHEC (<italic toggle="yes">E. coli</italic>-secreted proteins A, Intimin, and translocated intimin receptor), which blocked the bridge of bacterial hairs to adhere to the intestine <xref rid="b0625" ref-type="bibr">[125]</xref>. Compared to direct oral administration, CS encapsulation prevented the rapid degradation of antigens in the gastrointestinal tract. However, the low resistance of CS to acidic pH may limit its use as an oral vaccine carrier. Eudragit L100-coated CS further protects against antigen degradation under acidic conditions and reduce the adhesion of <italic toggle="yes">E. coli</italic>
<xref rid="b0630" ref-type="bibr">[126]</xref>. Nevertheless, the strategy of encapsulating the colonization factor alone only elicits limited humoral and cellular immunity.</p><p id="p0280">Therefore, a better option is to use biomaterials to simultaneously transport virulence factors involved in pathogenesis, including colonization factors and toxin antigens, to form recombinant conjugate vaccines and enhance the immunogenicity. For example, Nazarian <italic toggle="yes">et al.</italic> used another synthetic polymer, PLGA, with good biocompatibility to encapsulate ETEC with different serotypes of the colonization factors (CfaB, CstH, and CotA) as well as the labile toxin antigen to form an oral vaccine with PLGA-chimeric protein <xref rid="b0635" ref-type="bibr">[127]</xref>. The encapsulation of PLGA likewise protected the antigen from degradation in low pH conditions in the stomach. At the same time, the particle size of PLGA polymer after antigen encapsulation was around 250&#160;nm, and nanoparticles of this size can be phagocytosed by APCs and increase antigen uptake by lymphoid tissues <xref rid="b0640" ref-type="bibr">[128]</xref>. The results show that the vaccine prevented ETEC colonization while also neutralizing the toxic effects of toxins on intestinal epithelial cells. Importantly, oral administration of the chimeric vaccine to mice resulted in serum IgG and fecal IgA antibodies, <italic toggle="yes">i.e.</italic>, induced systemic and mucosal immune responses <xref rid="b0635" ref-type="bibr">[127]</xref>. In addition, chimeric ETEC- and EHEC-specific virulence proteins allow the design of vaccines against both bacteria, enhancing the immunogenicity of antigens and thus achieving the goal of preventing intestinal diseases caused by pathogenic <italic toggle="yes">E. coli</italic>
<xref rid="b0645" ref-type="bibr">[129]</xref>.</p><p id="p0285">Another common bacterium causing gastrointestinal infection is <italic toggle="yes">Shigella</italic>, including <italic toggle="yes">Shigella dysenteriae</italic>, <italic toggle="yes">Shigella flexneri</italic>, <italic toggle="yes">Shigella boydii</italic>, and <italic toggle="yes">Shigella sonnei</italic>
<xref rid="b0650" ref-type="bibr">[130]</xref>. <italic toggle="yes">Shigella</italic> primarily causes acute intestinal infection and symptoms range from mild watery diarrhea to severe bacterial dysentery. Since this bacterium is highly resistant to antibiotics and no effective vaccine is available, developing advanced vaccines is urgent.</p><p id="p0290">CS is one of the favorable contenders. Gilavand <italic toggle="yes">et al.</italic> piggybacked the MxiH antigen, a virulence protein in most gram-negative bacteria, with CS to form a mucosal vaccine <xref rid="b0655" ref-type="bibr">[131]</xref>. CS increased the permeability of tight junctions between cells <xref rid="b0660" ref-type="bibr">[132]</xref>, thus facilitating the passage of CS vaccine through the nasal mucosal barrier, activating nasal epithelial mucosal plasma cells and B cells, which produced mucosa-specific sIgA antibodies <xref rid="b0655" ref-type="bibr">[131]</xref>. However, lysozyme in the nasal mucosa degrades CS, causing a rapid release of antigens <xref rid="b0665" ref-type="bibr">[133]</xref>. Thermo-sensitive hydrogels have become carriers to prolong the persistence of antigens in the locus. A thermo-sensitive hydrogel consisting of Gantrez&#174;AN119 (Gz) and the surfactant PluronicF127 prolonged the adhesion of antigen at the mucosal site, while Gz was an activator of TLR2 and TLR4 that synergistically activated APCs and enhanced immunogenicity <xref rid="b0670" ref-type="bibr">[134]</xref>.</p><p id="p0295">Since <italic toggle="yes">Shigella</italic> is a gram-negative bacillus, the proteins and lipopolysaccharides present in <italic toggle="yes">Shigella</italic> are potential immunogens for antibacterial purposes <xref rid="b0615" ref-type="bibr">[123]</xref>. Some nanovaccines carrying protein antigens have been developed <xref rid="b0655" ref-type="bibr">[131]</xref>, <xref rid="b0675" ref-type="bibr">[135]</xref>, but it is challenging to bind structurally complex polysaccharide antigens to nanovaccines. Pan <italic toggle="yes">et al.</italic> designed a highly versatile and modular nanovaccine platform (Nano-B5 platform) <xref rid="b0090" ref-type="bibr">[18]</xref>. The peptide containing the AB<sub>5</sub> toxin B subunit protein was attached to the nanoplatform by a protein fusion domain, and the bacterial <italic toggle="yes">O</italic>-polysaccharide obtained from <italic toggle="yes">Shigela flexneri</italic> 2a was glycosylated and attached to the nanoplatform (<xref rid="f0015" ref-type="fig">Fig. 3</xref>). The nanovaccine bound to the monosialotetrahexosylganglioside (GM1) receptor on the surface of APCs and promoted antigen presentation <xref rid="b0680" ref-type="bibr">[136]</xref>. It activated both humoral and cellular immunity, producing neutralizing antibodies or directly destroying the pathogen, effectively preventing <italic toggle="yes">Shigella</italic> infection in mice <xref rid="b0090" ref-type="bibr">[18]</xref>. Furthermore, nanovaccines synthesized based on orthogonal and modular biosynthesis methods and combined with protein glycosylation technology selectively piggyback protein-glycan antigens in a controlled manner with good lymph node targeting and immune system activation <xref rid="b0685" ref-type="bibr">[137]</xref>.<fig id="f0015" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Self-assembling and modular Nano-B5 platform against <italic toggle="yes">Shigella</italic> infection. A) Synthetic strategies of nanovaccines. AB<sub>5</sub>-containing toxins, trimer-forming peptides, and polysaccharide antigens attached to nanoplatforms. B) Proportion of CD8<sup>+</sup> T cells in drain lymph nodes at three&#160;days after inoculation. C) Proportion of CD4<sup>+</sup> T cells in drain lymph nodes at three&#160;days after inoculation. D-G) Serum IgG concentration against lipopolysaccharide of <italic toggle="yes">Shigella flexneri 2a</italic> in mice. Reproduced with permission <xref rid="b0090" ref-type="bibr">[18]</xref>. Copyright 2020, John Wiley and Sons. Abbrrreviations: Al, aluminum hydroxide; C-OPS, cholera toxin-OPS; <italic toggle="yes">E. coli</italic>, <italic toggle="yes">Escherichia coli</italic>; IgG, immunoglobulin G; NP, nanoparticle; NP-OPS, polysaccharide conjugate vaccine nanoparticle; OPS, O antigen polysaccharide; PBS, phosphate-buffered saline; PglL, prokaryotic glycosyltransferase.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="lk00015" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="p0300">Among the pathogens causing gastrointestinal diseases, <italic toggle="yes">Escherichia coli</italic> and <italic toggle="yes">Shigella</italic> are the most primary contributors to fatal diarrheal diseases in children <xref rid="b0690" ref-type="bibr">[138]</xref>. The development of vaccines against them is crucial. Since the main infected population is infants and young children, children with very low maternal antibodies have a poor immune response to vaccines. Therefore, the design of vaccines is guided first by the principle of safety and then by the need to improve the immunogenicity of vaccines. Meanwhile, constructing the best experimental model is also an issue to consider.</p></sec></sec><sec id="s0055"><label>4</label><title>Conclusion and perspectives</title><p id="p0305">Biomaterials have been widely used to develop effective vaccines to prevent pathogenic microorganisms. In this review, we sort out the applications of immunologically effective biomaterials, especially polymers, to prevent viral and bacterial infection, providing a solid foundation for developing future epidemic vaccines. Immunogenically effective biomaterials have several advantages. First, polymers effectively load various components of the vaccines, such as antigens, small molecule adjuvants, and so forth. Second, modified polymers, such as Man-CS-Phe, actively target APCs to deliver antigens precisely <xref rid="b0315" ref-type="bibr">[63]</xref>. Third, polymers with biological properties, such as hybrid biological biomaterials generated using <italic toggle="yes">E. coli</italic> plasmids, achieve the whole process of APC antigen internalization, release, processing, and cross-presentation <xref rid="b0105" ref-type="bibr">[21]</xref>. Fourth, polymers with inherent immunomodulatory properties, such as cationic CS, also replace conventional adjuvants, such as Alum, to elicit more effective immune effects <xref rid="b0520" ref-type="bibr">[104]</xref>. Thus, advanced delivery systems based on biomaterials, especially polymers, provide immunogenicity of vaccines from all aspects. In addition, polymers that can be easily synthesized and modified, and can also be used in large-scale production. The hybrid nanoparticle made of protamine and lipid is a candidate that improve the mRNA transfection rate of existing COVID-19 mRNA vaccines. On the one hand, to improve the efficiency of vaccines, and on the other hand, to reduce the challenges caused by cold chain transport due to their accessible preservation properties <xref rid="b0160" ref-type="bibr">[32]</xref>.</p><p id="p0310">Despite the above advantages of polymer-based vaccines, some issues still need to be addressed to promote these conventional vaccines better. The first step is a thorough safety assessment of the polymers, especially since there may be unexpected cytotoxic or immune responses to their biodegradation products. In addition, there is a need to develop rigorous and uniform criteria for vaccine efficacy evaluation, which needs to be combined with the specific immune responses of various organisms against the pathogens of different infectious diseases. Overall, immunologically effective biomaterials remain promising platforms for vaccine delivery and deserve to be explored more deeply.</p></sec><sec id="s2221"><title>Acknowledgements</title><p id="p0320">This study was financially supported by the National Key Research and Development Program of China (Nos. 2022YFC2603500/2022YFC2603501 and 2021YFC2400600/ 2021YFC2400603/2021YFC2400604), the National Natural Science Foundation of China (Nos. 52273158, U21A2099, 52022095, 51973216, and 51873207), the Science and Technology Development Program of Jilin Province (Nos. 20220204018YY, 20210509005RQ, 20210504001GH, and 20200404182YY), the Youth Innovation Promotion Association of Chinese Academy of Sciences (No. 2019230), the Special Project for City&#8211;Academy Scientific and Technological Innovation Cooperation of Changchun (No. 21SH14), and the Fundamental Research Funds for the Central Universities, JLU.</p></sec><sec id="s3336"><title>Conflict of interest statement</title><p id="p0315">The authors declare that there are no conflicts of interest.</p></sec><sec id="s1111"><title>Author contributions</title><p id="p6332"><bold>Qi Wei:</bold> Conceptualization, Validation, Investigation, Writing - original draft. <bold>Shixian Liu:</bold> Validation, Investigation, Writing - original draft. <bold>Xu Huang:</bold> Writing - review &amp; editing. <bold>Hua Xin:</bold> Writing - review &amp; editing, Supervision. <bold>Jianxun Ding:</bold> Conceptualization, Writing - review &amp; editing, Supervision, Project administration, Funding acquisition.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><label>1</label><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name name-style="western"><surname>Hodgson</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Mansatta</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mallett</surname><given-names>G.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>V.</given-names></name><name name-style="western"><surname>Emary</surname><given-names>K.R.W.</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>A.J.</given-names></name></person-group><article-title>What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2</article-title><source>Lancet Infect. Dis.</source><volume>21</volume><year>2021</year><fpage>e26</fpage><lpage>e35</lpage><pub-id pub-id-type="doi">10.1016/s1473-3099(20)30773-8</pub-id><pub-id pub-id-type="pmid">33125914</pub-id><pub-id pub-id-type="pmcid">PMC7837315</pub-id></element-citation></ref><ref id="b0010"><label>2</label><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name name-style="western"><surname>Chowell</surname><given-names>G.</given-names></name><name name-style="western"><surname>Echevarr&#237;a-Zuno</surname><given-names>S.</given-names></name><name name-style="western"><surname>Viboud</surname><given-names>C.</given-names></name><name name-style="western"><surname>Simonsen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tamerius</surname><given-names>J.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Borja-Aburto</surname><given-names>V.H.</given-names></name></person-group><article-title>Characterizing the epidemiology of the 2009 influenza A/H1N1 pandemic in Mexico</article-title><source>PLoS Med.</source><volume>8</volume><year>2011</year><object-id pub-id-type="publisher-id">e1000436</object-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1000436</pub-id><pub-id pub-id-type="pmcid">PMC3101203</pub-id><pub-id pub-id-type="pmid">21629683</pub-id></element-citation></ref><ref id="b0015"><label>3</label><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name name-style="western"><surname>Sharp</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>B.H.</given-names></name></person-group><article-title>Origins of HIV and the AIDS pandemic</article-title><source>Cold Spring Harbor Perspect. Med.</source><volume>1</volume><year>2011</year><object-id pub-id-type="publisher-id">a006841</object-id><pub-id pub-id-type="doi">10.1101/cshperspect.a006841</pub-id><pub-id pub-id-type="pmcid">PMC3234451</pub-id><pub-id pub-id-type="pmid">22229120</pub-id></element-citation></ref><ref id="b0020"><label>4</label><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name name-style="western"><surname>Gerlich</surname><given-names>W.H.</given-names></name></person-group><article-title>Medical virology of hepatitis B: How it began and where we are now</article-title><source>Virol. J.</source><volume>10</volume><year>2013</year><object-id pub-id-type="publisher-id">239</object-id><pub-id pub-id-type="doi">10.1186/1743-422x-10-239</pub-id><pub-id pub-id-type="pmcid">PMC3729363</pub-id><pub-id pub-id-type="pmid">23870415</pub-id></element-citation></ref><ref id="b0025"><label>5</label><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name name-style="western"><surname>Piralam</surname><given-names>B.</given-names></name><name name-style="western"><surname>Prosperi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Thamthitiwat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bunthi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sawatwong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Higdon</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Paveenkittiporn</surname><given-names>W.</given-names></name><name name-style="western"><surname>Maloney</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Baggett</surname><given-names>H.C.</given-names></name><etal/></person-group><article-title>Pneumococcal colonization prevalence and density among Thai children with severe pneumonia and community controls</article-title><source>PLoS One</source><volume>15</volume><year>2020</year><object-id pub-id-type="publisher-id">e0232151</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0232151</pub-id><pub-id pub-id-type="pmcid">PMC7190126</pub-id><pub-id pub-id-type="pmid">32348330</pub-id></element-citation></ref><ref id="b0030"><label>6</label><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name name-style="western"><surname>Koch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mizrahi</surname><given-names>V.</given-names></name></person-group><article-title>Mycobacterium tuberculosis</article-title><source>Trends Microbiol.</source><volume>26</volume><year>2018</year><fpage>555</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2018.02.012</pub-id><pub-id pub-id-type="pmid">29580884</pub-id></element-citation></ref><ref id="b0035"><label>7</label><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name name-style="western"><surname>Khairy</surname><given-names>R.M.M.</given-names></name><name name-style="western"><surname>Fathy</surname><given-names>Z.A.</given-names></name><name name-style="western"><surname>Mahrous</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Abdelrahim</surname><given-names>S.S.</given-names></name></person-group><article-title>Prevalence, phylogeny, and antimicrobial resistance of <italic toggle="yes">Escherichia coli</italic> pathotypes isolated from children less than 5 years old with community acquired diarrhea in Upper Egypt</article-title><source>BMC Infect. Dis.</source><volume>20</volume><year>2020</year><object-id pub-id-type="publisher-id">908</object-id><pub-id pub-id-type="doi">10.1186/s12879-020-05664-6</pub-id><pub-id pub-id-type="pmcid">PMC7708180</pub-id><pub-id pub-id-type="pmid">33256619</pub-id></element-citation></ref><ref id="b0040"><label>8</label><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name name-style="western"><surname>Blair</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Webber</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Baylay</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Ogbolu</surname><given-names>D.O.</given-names></name><name name-style="western"><surname>Piddock</surname><given-names>L.J.</given-names></name></person-group><article-title>Molecular mechanisms of antibiotic resistance</article-title><source>Nat. Rev. Microbiol.</source><volume>13</volume><year>2015</year><fpage>42</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3380</pub-id><pub-id pub-id-type="pmid">25435309</pub-id></element-citation></ref><ref id="b0045"><label>9</label><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mandl</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Black</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Gregorio</surname><given-names>E.</given-names></name></person-group><article-title>Vaccines for the twenty-first century society</article-title><source>Nat. Rev. Immunol.</source><volume>11</volume><year>2011</year><fpage>865</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1038/nri3085</pub-id><pub-id pub-id-type="pmid">22051890</pub-id><pub-id pub-id-type="pmcid">PMC7098427</pub-id></element-citation></ref><ref id="b0050"><label>10</label><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>R.</given-names></name></person-group><article-title>Immunological mechanisms of vaccination</article-title><source>Nat. Immunol.</source><volume>12</volume><year>2011</year><fpage>509</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/ni.2039</pub-id><pub-id pub-id-type="pmid">21739679</pub-id><pub-id pub-id-type="pmcid">PMC3253344</pub-id></element-citation></ref><ref id="b0055"><label>11</label><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name name-style="western"><surname>Gerberding</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>B.F.</given-names></name></person-group><article-title>Vaccine innovations&#8212;Past and future</article-title><source>N. Engl. J. Med.</source><volume>384</volume><year>2021</year><fpage>393</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1056/NEJMp2029466</pub-id><pub-id pub-id-type="pmid">33535287</pub-id></element-citation></ref><ref id="b0060"><label>12</label><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name name-style="western"><surname>Maruggi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ulmer</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D.</given-names></name></person-group><article-title>mRNA as a transformative technology for vaccine development to control infectious diseases</article-title><source>Mol. Ther.</source><volume>27</volume><year>2019</year><fpage>757</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2019.01.020</pub-id><pub-id pub-id-type="pmid">30803823</pub-id><pub-id pub-id-type="pmcid">PMC6453507</pub-id></element-citation></ref><ref id="b0065"><label>13</label><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name></person-group><article-title>Biosafety chemistry and biosafety materials: A new perspective to solve biosafety problems</article-title><source>Biosaf. Health</source><volume>4</volume><year>2022</year><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.bsheal.2022.01.001</pub-id><pub-id pub-id-type="pmid">35013725</pub-id><pub-id pub-id-type="pmcid">PMC8730778</pub-id></element-citation></ref><ref id="b0070"><label>14</label><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>Advanced biosafety materials for prevention and theranostics of biosafety issues</article-title><source>Biosaf. Health</source><volume>4</volume><year>2022</year><fpage>59</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.bsheal.2022.03.011</pub-id><pub-id pub-id-type="pmid">35313507</pub-id><pub-id pub-id-type="pmcid">PMC8926432</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="expression-of-concern" ext-link-type="pmc" xlink:href="PMC11973487"/></element-citation></ref><ref id="b0075"><label>15</label><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name name-style="western"><surname>Khanifar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Salmanian</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Haji Hosseini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Amani</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kazemi</surname><given-names>R.</given-names></name></person-group><article-title>Chitosan nano-structure loaded with recombinant <italic toggle="yes">E. coli</italic> O157: H7 antigens as a vaccine candidate can effectively increase immunization capacity</article-title><source>Artif. Cells Nanomed. Biotechnol.</source><volume>47</volume><year>2019</year><fpage>2593</fpage><lpage>2604</lpage><pub-id pub-id-type="doi">10.1080/21691401.2019.1629947</pub-id><pub-id pub-id-type="pmid">31240960</pub-id></element-citation></ref><ref id="b0080"><label>16</label><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name name-style="western"><surname>Wibowo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jorritsma</surname><given-names>S.H.T.</given-names></name><name name-style="western"><surname>Gonzaga</surname><given-names>Z.J.</given-names></name><name name-style="western"><surname>Evert</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>B.H.A.</given-names></name></person-group><article-title>Polymeric nanoparticle vaccines to combat emerging and pandemic threats</article-title><source>Biomaterials</source><volume>268</volume><year>2021</year><object-id pub-id-type="publisher-id">120597</object-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.120597</pub-id><pub-id pub-id-type="pmcid">PMC7834201</pub-id><pub-id pub-id-type="pmid">33360074</pub-id></element-citation></ref><ref id="b0085"><label>17</label><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Advanced bioactive nanomaterials for biomedical applications</article-title><source>Exploration</source><volume>1</volume><year>2021</year><object-id pub-id-type="publisher-id">20210089</object-id><pub-id pub-id-type="doi">10.1002/EXP.20210089</pub-id><pub-id pub-id-type="pmcid">PMC10191050</pub-id><pub-id pub-id-type="pmid">37323697</pub-id></element-citation></ref><ref id="b0090"><label>18</label><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qing</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Biosynthesis of self-assembled proteinaceous nanoparticles for vaccination</article-title><source>Adv. Mater.</source><volume>32</volume><year>2020</year><object-id pub-id-type="publisher-id">e2002940</object-id><pub-id pub-id-type="doi">10.1002/adma.202002940</pub-id><pub-id pub-id-type="pmid">32881121</pub-id></element-citation></ref><ref id="b0095"><label>19</label><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>Immunologically effective biomaterials</article-title><source>ACS Appl. Mater. Interfaces</source><volume>13</volume><year>2021</year><fpage>56719</fpage><lpage>56724</lpage><pub-id pub-id-type="doi">10.1021/acsami.1c14781</pub-id><pub-id pub-id-type="pmid">34797622</pub-id></element-citation></ref><ref id="b0100"><label>20</label><element-citation publication-type="journal" id="h0100"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Song</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>Immunomodulatory nanosystems</article-title><source>Adv. Sci.</source><volume>6</volume><year>2019</year><object-id pub-id-type="publisher-id">1900101</object-id><pub-id pub-id-type="doi">10.1002/advs.201900101</pub-id><pub-id pub-id-type="pmcid">PMC6724480</pub-id><pub-id pub-id-type="pmid">31508270</pub-id></element-citation></ref><ref id="b0105"><label>21</label><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Beitelshees</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R.J.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Andreadis</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Hakansson</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Pfeifer</surname><given-names>B.A.</given-names></name></person-group><article-title><italic toggle="yes">In situ</italic> pneumococcal vaccine production and delivery through a hybrid biological-biomaterial vector</article-title><source>Sci. Adv.</source><volume>2</volume><year>2016</year><object-id pub-id-type="publisher-id">e1600264</object-id><pub-id pub-id-type="doi">10.1126/sciadv.1600264</pub-id><pub-id pub-id-type="pmcid">PMC4942325</pub-id><pub-id pub-id-type="pmid">27419235</pub-id></element-citation></ref><ref id="b0110"><label>22</label><element-citation publication-type="journal" id="h0110"><person-group person-group-type="author"><name name-style="western"><surname>Shim</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Quan</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Jere</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>C.H.</given-names></name><etal/></person-group><article-title>Intranasal immunization with plasmid DNA encoding spike protein of SARS-coronavirus/polyethylenimine nanoparticles elicits antigen-specific humoral and cellular immune responses</article-title><source>BMC Immunol.</source><volume>11</volume><year>2010</year><object-id pub-id-type="publisher-id">65</object-id><pub-id pub-id-type="doi">10.1186/1471-2172-11-65</pub-id><pub-id pub-id-type="pmcid">PMC3023737</pub-id><pub-id pub-id-type="pmid">21194475</pub-id></element-citation></ref><ref id="b0115"><label>23</label><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Farzan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Choe</surname><given-names>H.</given-names></name></person-group><article-title>Mechanisms of SARS-CoV-2 entry into cells</article-title><source>Nat. Rev. Mol. Cell Biol.</source><volume>23</volume><year>2022</year><fpage>3</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1038/s41580-021-00418-x</pub-id><pub-id pub-id-type="pmid">34611326</pub-id><pub-id pub-id-type="pmcid">PMC8491763</pub-id></element-citation></ref><ref id="b0120"><label>24</label><element-citation publication-type="journal" id="h0120"><person-group person-group-type="author"><name name-style="western"><surname>Mullard</surname><given-names>A.</given-names></name></person-group><article-title>COVID-19 vaccine development pipeline gears up</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>1751</fpage><lpage>1752</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(20)31252-6</pub-id><pub-id pub-id-type="pmid">32505245</pub-id><pub-id pub-id-type="pmcid">PMC7272155</pub-id></element-citation></ref><ref id="b0125"><label>25</label><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name name-style="western"><surname>Polack</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mather</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dormitzer</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>&#350;ahin</surname><given-names>U.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>K.U.</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>W.C.</given-names></name><etal/></person-group><article-title>Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine</article-title><source>N. Engl. J. Med.</source><volume>383</volume><year>2020</year><fpage>2603</fpage><lpage>2615</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmid">33301246</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id></element-citation></ref><ref id="b0130"><label>26</label><element-citation publication-type="journal" id="h0130"><person-group person-group-type="author"><name name-style="western"><surname>Telenti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Arvin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Corey</surname><given-names>L.</given-names></name><name name-style="western"><surname>Corti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Garc&#237;a-Sastre</surname><given-names>A.</given-names></name><name name-style="western"><surname>Garry</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Virgin</surname><given-names>H.W.</given-names></name></person-group><article-title>After the pandemic: Perspectives on the future trajectory of COVID-19</article-title><source>Nature</source><volume>596</volume><year>2021</year><fpage>495</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03792-w</pub-id><pub-id pub-id-type="pmid">34237771</pub-id></element-citation></ref><ref id="b0135"><label>27</label><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Beiss</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fiering</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>N.F.</given-names></name></person-group><article-title>COVID-19 vaccine frontrunners and their nanotechnology design</article-title><source>ACS Nano</source><volume>14</volume><year>2020</year><fpage>12522</fpage><lpage>12537</lpage><pub-id pub-id-type="doi">10.1021/acsnano.0c07197</pub-id><pub-id pub-id-type="pmid">33034449</pub-id></element-citation></ref><ref id="b0140"><label>28</label><mixed-citation publication-type="other" id="h5552">Z. Chagla, The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 &#8805;7 days after the 2nd dose, Ann. Intern. Med. 174 (2021) JC15, doi: 10.7326/acpj202102160-015.<pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/ACPJ202102160-015</pub-id><pub-id pub-id-type="pmid">33524290</pub-id></mixed-citation></ref><ref id="b0145"><label>29</label><element-citation publication-type="journal" id="h0145"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Beiss</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Ortega-Rivera</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Wirth</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sack</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pokorski</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>N.F.</given-names></name></person-group><article-title>COVID-19 vaccine development and a potential nanomaterial path forward</article-title><source>Nat. Nanotechnol.</source><volume>15</volume><year>2020</year><fpage>646</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1038/s41565-020-0737-y</pub-id><pub-id pub-id-type="pmid">32669664</pub-id></element-citation></ref><ref id="b0150"><label>30</label><element-citation publication-type="journal" id="h0150"><person-group person-group-type="author"><name name-style="western"><surname>Fornaguera</surname><given-names>C.</given-names></name><name name-style="western"><surname>D&#237;az-Caballero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garc&#237;a-Fernandez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Olmo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Stampa-L&#243;pez Pinto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Naval&#243;n-L&#243;pez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guerra-Rebollo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Borr&#243;s</surname><given-names>S.</given-names></name></person-group><article-title>Synthesis and characterization of mRNA-loaded poly(&#946;-amino esters) nanoparticles for vaccination purposes</article-title><source>J. Vis. Exp.</source><volume>174</volume><year>2021</year><object-id pub-id-type="publisher-id">e62889</object-id><pub-id pub-id-type="doi">10.3791/62889</pub-id><pub-id pub-id-type="pmid">34459811</pub-id></element-citation></ref><ref id="b0155"><label>31</label><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name name-style="western"><surname>Mukherjee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Kalyan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Achrol</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Kesari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yenugonda</surname><given-names>V.M.</given-names></name></person-group><article-title>Lipid-polymer hybrid nanoparticles as a next-generation drug delivery platform: State of the art, emerging technologies, and perspectives</article-title><source>Int. J. Nanomed.</source><volume>14</volume><year>2019</year><fpage>1937</fpage><lpage>1952</lpage><pub-id pub-id-type="doi">10.2147/ijn.S198353</pub-id><pub-id pub-id-type="pmcid">PMC6430183</pub-id><pub-id pub-id-type="pmid">30936695</pub-id></element-citation></ref><ref id="b0160"><label>32</label><element-citation publication-type="journal" id="h0160"><person-group person-group-type="author"><name name-style="western"><surname>Siewert</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Haas</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cornet</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nogueira</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Nawroth</surname><given-names>T.</given-names></name><name name-style="western"><surname>Blanchet</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Svergun</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Radsak</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Sahin</surname><given-names>U.</given-names></name><name name-style="western"><surname>Langguth</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Hybrid biopolymer and lipid nanoparticles with improved transfection efficacy for mRNA</article-title><source>Cells</source><volume>9</volume><year>2020</year><object-id pub-id-type="publisher-id">2034</object-id><pub-id pub-id-type="doi">10.3390/cells9092034</pub-id><pub-id pub-id-type="pmcid">PMC7563888</pub-id><pub-id pub-id-type="pmid">32899484</pub-id></element-citation></ref><ref id="b0165"><label>33</label><element-citation publication-type="journal" id="h0165"><person-group person-group-type="author"><name name-style="western"><surname>Silveira</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mendon&#231;a</surname><given-names>M.</given-names></name></person-group><article-title>DNA vaccines against COVID-19: Perspectives and challenges</article-title><source>Life Sci.</source><volume>267</volume><year>2021</year><object-id pub-id-type="publisher-id">118919</object-id><pub-id pub-id-type="doi">10.1016/j.lfs.2020.118919</pub-id><pub-id pub-id-type="pmcid">PMC7749647</pub-id><pub-id pub-id-type="pmid">33352173</pub-id></element-citation></ref><ref id="b0170"><label>34</label><element-citation publication-type="journal" id="h0170"><person-group person-group-type="author"><name name-style="western"><surname>Gurnani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Blakney</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Yeow</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bouton</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Shattock</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>C.</given-names></name></person-group><article-title>An improved synthesis of poly(amidoamine)s for complexation with self-amplifying RNA and effective transfection</article-title><source>Polym. Chem.</source><volume>11</volume><year>2020</year><fpage>5861</fpage><lpage>5869</lpage><pub-id pub-id-type="doi">10.1039/d0py00912a</pub-id></element-citation></ref><ref id="b0175"><label>35</label><element-citation publication-type="journal" id="h0175"><person-group person-group-type="author"><name name-style="western"><surname>Comberlato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Paloja</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bastings</surname><given-names>M.M.C.</given-names></name></person-group><article-title>Nucleic acids presenting polymer nanomaterials as vaccine adjuvants</article-title><source>J. Mater. Chem. B</source><volume>7</volume><year>2019</year><fpage>6321</fpage><lpage>6346</lpage><pub-id pub-id-type="doi">10.1039/c9tb01222b</pub-id><pub-id pub-id-type="pmid">31460563</pub-id></element-citation></ref><ref id="b0180"><label>36</label><element-citation publication-type="journal" id="h0180"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Su</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>Separable microneedle patch to protect and deliver DNA nanovaccines against COVID-19</article-title><source>ACS Nano</source><volume>15</volume><year>2021</year><fpage>14347</fpage><lpage>14359</lpage><pub-id pub-id-type="doi">10.1021/acsnano.1c03252</pub-id><pub-id pub-id-type="pmid">34472328</pub-id></element-citation></ref><ref id="b0185"><label>37</label><element-citation publication-type="journal" id="h0185"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Chag</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Poongavanam</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Biter</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Ewere</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Rezende</surname><given-names>W.</given-names></name><name name-style="western"><surname>Seid</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Hudspeth</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Pollet</surname><given-names>J.</given-names></name><name name-style="western"><surname>McAtee</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Strych</surname><given-names>U.</given-names></name><name name-style="western"><surname>Bottazzi</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Hotez</surname><given-names>P.J.</given-names></name></person-group><article-title>Optimization of the production process and characterization of the yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1), a SARS vaccine candidate</article-title><source>J. Pharm. Sci.</source><volume>106</volume><year>2017</year><fpage>1961</fpage><lpage>1970</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2017.04.037</pub-id><pub-id pub-id-type="pmid">28456726</pub-id><pub-id pub-id-type="pmcid">PMC5612335</pub-id></element-citation></ref><ref id="b0190"><label>38</label><element-citation publication-type="journal" id="h0190"><person-group person-group-type="author"><name name-style="western"><surname>Gale</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Meany</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Grosskopf</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Adamska</surname><given-names>J.</given-names></name><name name-style="western"><surname>Picece</surname><given-names>V.</given-names></name><name name-style="western"><surname>d&#8217;Aquino</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Pulendran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Appel</surname><given-names>E.A.</given-names></name></person-group><article-title>Hydrogel-based slow release of a receptor-binding domain subunit vaccine elicits neutralizing antibody responses against SARS-CoV-2</article-title><source>Adv. Mater.</source><volume>33</volume><year>2021</year><fpage>e2104362</fpage><pub-id pub-id-type="doi">10.1002/adma.202104362</pub-id><pub-id pub-id-type="pmid">34651342</pub-id><pub-id pub-id-type="pmcid">PMC8646307</pub-id></element-citation></ref><ref id="b0195"><label>39</label><element-citation publication-type="journal" id="h0195"><person-group person-group-type="author"><name name-style="western"><surname>Gray</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Raczy</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Briquez</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Marchell</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Alpar</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Kwissa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Swartz</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Hubbell</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens <italic toggle="yes">via</italic> conjugation to a polymeric glyco-adjuvant</article-title><source>Biomaterials</source><volume>278</volume><year>2021</year><object-id pub-id-type="publisher-id">121159</object-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.121159</pub-id><pub-id pub-id-type="pmcid">PMC8482845</pub-id><pub-id pub-id-type="pmid">34634664</pub-id></element-citation></ref><ref id="b0200"><label>40</label><element-citation publication-type="journal" id="h0200"><person-group person-group-type="author"><name name-style="western"><surname>Bermejo-Jambrina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eder</surname><given-names>J.</given-names></name><name name-style="western"><surname>Helgers</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Hertoghs</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nijmeijer</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Stunnenberg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Geijtenbeek</surname><given-names>T.B.H.</given-names></name></person-group><article-title>C-type lectin receptors in antiviral immunity and viral escape</article-title><source>Front. Immunol.</source><volume>9</volume><year>2018</year><fpage>590</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.00590</pub-id><pub-id pub-id-type="pmid">29632536</pub-id><pub-id pub-id-type="pmcid">PMC5879224</pub-id></element-citation></ref><ref id="b0205"><label>41</label><element-citation publication-type="journal" id="h0205"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name></person-group><article-title>Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2</article-title><source>Science</source><volume>367</volume><year>2020</year><fpage>1444</fpage><lpage>1448</lpage><pub-id pub-id-type="doi">10.1126/science.abb2762</pub-id><pub-id pub-id-type="pmid">32132184</pub-id><pub-id pub-id-type="pmcid">PMC7164635</pub-id></element-citation></ref><ref id="b0210"><label>42</label><element-citation publication-type="journal" id="h0210"><person-group person-group-type="author"><name name-style="western"><surname>Stone</surname><given-names>B.D.</given-names></name></person-group><article-title>PEG skin testing for COVID-19 vaccine allergy</article-title><source>J. Allergy Clin. Immunol. Pract.</source><volume>9</volume><year>2021</year><fpage>1765</fpage><pub-id pub-id-type="doi">10.1016/j.jaip.2021.02.016</pub-id><pub-id pub-id-type="pmcid">PMC8024682</pub-id><pub-id pub-id-type="pmid">33838847</pub-id></element-citation></ref><ref id="b0215"><label>43</label><element-citation publication-type="journal" id="h0215"><person-group person-group-type="author"><name name-style="western"><surname>Pelosi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Duce</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wurm</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Tin&#232;</surname><given-names>M.R.</given-names></name></person-group><article-title>Effect of polymer hydrophilicity and molar mass on the properties of the protein in protein-polymer conjugates: The case of PPEylated myoglobin</article-title><source>Biomacromolecules</source><volume>22</volume><year>2021</year><fpage>1932</fpage><lpage>1943</lpage><pub-id pub-id-type="doi">10.1021/acs.biomac.1c00058</pub-id><pub-id pub-id-type="pmid">33830737</pub-id><pub-id pub-id-type="pmcid">PMC8154264</pub-id></element-citation></ref><ref id="b0220"><label>44</label><element-citation publication-type="journal" id="h0220"><person-group person-group-type="author"><name name-style="western"><surname>Taubenberger</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Kash</surname><given-names>J.C.</given-names></name></person-group><article-title>Influenza virus evolution, host adaptation, and pandemic formation</article-title><source>Cell Host Microbe</source><volume>7</volume><year>2010</year><fpage>440</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2010.05.009</pub-id><pub-id pub-id-type="pmid">20542248</pub-id><pub-id pub-id-type="pmcid">PMC2892379</pub-id></element-citation></ref><ref id="b0225"><label>45</label><element-citation publication-type="journal" id="h0225"><person-group person-group-type="author"><name name-style="western"><surname>Krammer</surname><given-names>F.</given-names></name></person-group><article-title>The human antibody response to influenza A virus infection and vaccination</article-title><source>Nat. Rev. Immunol.</source><volume>19</volume><year>2019</year><fpage>383</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0143-6</pub-id><pub-id pub-id-type="pmid">30837674</pub-id></element-citation></ref><ref id="b0230"><label>46</label><element-citation publication-type="journal" id="h0230"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ly</surname><given-names>H.</given-names></name></person-group><article-title>Advances in development and application of influenza vaccines</article-title><source>Front. Immunol.</source><volume>12</volume><year>2021</year><object-id pub-id-type="publisher-id">711997</object-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.711997</pub-id><pub-id pub-id-type="pmcid">PMC8313855</pub-id><pub-id pub-id-type="pmid">34326849</pub-id></element-citation></ref><ref id="b0235"><label>47</label><element-citation publication-type="journal" id="h0235"><person-group person-group-type="author"><name name-style="western"><surname>Sano</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ainai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>H.</given-names></name></person-group><article-title>The road to a more effective influenza vaccine: Up to date studies and future prospects</article-title><source>Vaccine</source><volume>35</volume><year>2017</year><fpage>5388</fpage><lpage>5395</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.08.034</pub-id><pub-id pub-id-type="pmid">28866292</pub-id></element-citation></ref><ref id="b0240"><label>48</label><element-citation publication-type="journal" id="h0240"><person-group person-group-type="author"><name name-style="western"><surname>Tanishita</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ukawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tomono</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tsujioka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Miyata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tobita</surname><given-names>E.</given-names></name><name name-style="western"><surname>Uto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Baba</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sakuma</surname><given-names>S.</given-names></name></person-group><article-title>Cross-protective abilities of hyaluronic acid modified with tetraglycine-L-octaarginine as a mucosal adjuvant against infection with heterologous influenza viruses</article-title><source>Bioconjug. Chem.</source><volume>30</volume><year>2019</year><fpage>3028</fpage><lpage>3037</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.9b00644</pub-id><pub-id pub-id-type="pmid">31738536</pub-id></element-citation></ref><ref id="b0245"><label>49</label><element-citation publication-type="journal" id="h0245"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Talactac</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C.J.</given-names></name></person-group><article-title>Mucosal immunization with recombinant influenza hemagglutinin protein and poly(&#947;-glutamate)/chitosan nanoparticles induces protection against highly pathogenic influenza A virus</article-title><source>Vet. Microbiol.</source><volume>160</volume><year>2012</year><fpage>277</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2012.05.035</pub-id><pub-id pub-id-type="pmid">22763171</pub-id></element-citation></ref><ref id="b0250"><label>50</label><element-citation publication-type="journal" id="h0250"><person-group person-group-type="author"><name name-style="western"><surname>Talayev</surname><given-names>V.</given-names></name><name name-style="western"><surname>Zaichenko</surname><given-names>I.</given-names></name><name name-style="western"><surname>Svetlova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matveichev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Babaykina</surname><given-names>O.</given-names></name><name name-style="western"><surname>Voronina</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mironov</surname><given-names>A.</given-names></name></person-group><article-title>Low-dose influenza vaccine Grippol Quadrivalent with adjuvant polyoxidonium induces a T helper-2 mediated humoral immune response and increases NK cell activity</article-title><source>Vaccine</source><volume>38</volume><year>2020</year><fpage>6645</fpage><lpage>6655</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.07.053</pub-id><pub-id pub-id-type="pmid">32873403</pub-id></element-citation></ref><ref id="b0255"><label>51</label><element-citation publication-type="journal" id="h0255"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Na</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.O.</given-names></name><name name-style="western"><surname>Yeom</surname><given-names>M.</given-names></name><name name-style="western"><surname>Park</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>C.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Le</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Song</surname><given-names>D.</given-names></name><name name-style="western"><surname>Haam</surname><given-names>S.</given-names></name></person-group><article-title>Cationic poly(amino acid) vaccine adjuvant for promoting both cell-mediated and humoral immunity against influenza virus</article-title><source>Adv. Healthc. Mater.</source><volume>8</volume><year>2019</year><object-id pub-id-type="publisher-id">e1800953</object-id><pub-id pub-id-type="doi">10.1002/adhm.201800953</pub-id><pub-id pub-id-type="pmid">30549426</pub-id></element-citation></ref><ref id="b0260"><label>52</label><element-citation publication-type="journal" id="h0260"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>Progress in the development of universal influenza vaccines</article-title><source>Viruses</source><volume>12</volume><year>2020</year><object-id pub-id-type="publisher-id">1033</object-id><pub-id pub-id-type="doi">10.3390/v12091033</pub-id><pub-id pub-id-type="pmcid">PMC7551969</pub-id><pub-id pub-id-type="pmid">32957468</pub-id></element-citation></ref><ref id="b0265"><label>53</label><element-citation publication-type="journal" id="h0265"><person-group person-group-type="author"><name name-style="western"><surname>Saouaf</surname><given-names>O.M.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A.A.A.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Gale</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Grosskopf</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Picece</surname><given-names>V.</given-names></name><name name-style="western"><surname>Appel</surname><given-names>E.A.</given-names></name></person-group><article-title>Modulation of injectable hydrogel properties for slow co-delivery of influenza subunit vaccine components enhance the potency of humoral immunity</article-title><source>J. Biomed. Mater. Res. A</source><volume>109</volume><year>2021</year><fpage>2173</fpage><lpage>2186</lpage><pub-id pub-id-type="doi">10.1002/jbm.a.37203</pub-id><pub-id pub-id-type="pmid">33955657</pub-id><pub-id pub-id-type="pmcid">PMC8518857</pub-id></element-citation></ref><ref id="b0270"><label>54</label><element-citation publication-type="journal" id="h0270"><person-group person-group-type="author"><name name-style="western"><surname>Roth</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Saouaf</surname><given-names>O.M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A.A.A.</given-names></name><name name-style="western"><surname>Gale</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Hern&#225;ndez</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Idoyaga</surname><given-names>J.</given-names></name><name name-style="western"><surname>Appel</surname><given-names>E.A.</given-names></name></person-group><article-title>Prolonged codelivery of hemagglutinin and a TLR7/8 agonist in a supramolecular polymer-nanoparticle hydrogel enhances potency and breadth of influenza vaccination</article-title><source>ACS Biomater. Sci. Eng.</source><volume>7</volume><year>2021</year><fpage>1889</fpage><lpage>1899</lpage><pub-id pub-id-type="doi">10.1021/acsbiomaterials.0c01496</pub-id><pub-id pub-id-type="pmid">33404236</pub-id><pub-id pub-id-type="pmcid">PMC8153386</pub-id></element-citation></ref><ref id="b0275"><label>55</label><element-citation publication-type="journal" id="h0275"><person-group person-group-type="author"><name name-style="western"><surname>Toy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Keenum</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Pradhan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Phang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chukwu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>L.A.H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kozlowski</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hosten</surname><given-names>J.</given-names></name><name name-style="western"><surname>Suthar</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>K.</given-names></name></person-group><article-title>TLR7 and RIG-I dual-adjuvant loaded nanoparticles drive broadened and synergistic responses in dendritic cells <italic toggle="yes">in vitro</italic> and generate unique cellular immune responses in influenza vaccination</article-title><source>J. Control. Release</source><volume>330</volume><year>2021</year><fpage>866</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.10.060</pub-id><pub-id pub-id-type="pmid">33160004</pub-id><pub-id pub-id-type="pmcid">PMC7906919</pub-id></element-citation></ref><ref id="b0280"><label>56</label><element-citation publication-type="journal" id="h0280"><person-group person-group-type="author"><name name-style="western"><surname>Knight</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Gilchuk</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Sevimli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Suryadevara</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wang-Bishop</surname><given-names>L.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Crowe</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Joyce</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>J.T.</given-names></name></person-group><article-title>Mucosal immunization with a pH-responsive nanoparticle vaccine induces protective CD8<sup>+</sup> lung-resident memory T cells</article-title><source>ACS Nano</source><volume>13</volume><year>2019</year><fpage>10939</fpage><lpage>10960</lpage><pub-id pub-id-type="doi">10.1021/acsnano.9b00326</pub-id><pub-id pub-id-type="pmid">31553872</pub-id><pub-id pub-id-type="pmcid">PMC6832804</pub-id></element-citation></ref><ref id="b0285"><label>57</label><element-citation publication-type="journal" id="h0285"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>K.</given-names></name><name name-style="western"><surname>Senapati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Darling</surname><given-names>R.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jefferson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Uz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Verhoeven</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kohut</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mallapragada</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wannemuehler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Narasimhan</surname><given-names>B.</given-names></name></person-group><article-title>Single dose combination nanovaccine provides protection against influenza A virus in young and aged mice</article-title><source>Biomater. Sci.</source><volume>7</volume><year>2019</year><fpage>809</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1039/c8bm01443d</pub-id><pub-id pub-id-type="pmid">30663733</pub-id></element-citation></ref><ref id="b0290"><label>58</label><element-citation publication-type="journal" id="h0290"><person-group person-group-type="author"><name name-style="western"><surname>Ray</surname><given-names>G.</given-names></name></person-group><article-title>Trends of chronic liver disease in a tertiary care referral hospital in Eastern India</article-title><source>Indian J. Public Health</source><volume>58</volume><year>2014</year><fpage>186</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.4103/0019-557x.138630</pub-id><pub-id pub-id-type="pmid">25116825</pub-id></element-citation></ref><ref id="b0295"><label>59</label><element-citation publication-type="journal" id="h0295"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gane</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kao</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Dusheiko</surname><given-names>G.</given-names></name></person-group><article-title>Hepatitis B virus: Advances in prevention, diagnosis, and therapy</article-title><source>Clin. Microbiol. Rev.</source><volume>33</volume><year>2020</year><object-id pub-id-type="publisher-id">e00046-19</object-id><pub-id pub-id-type="doi">10.1128/cmr.00046-19</pub-id><pub-id pub-id-type="pmcid">PMC7048015</pub-id><pub-id pub-id-type="pmid">32102898</pub-id></element-citation></ref><ref id="b0300"><label>60</label><element-citation publication-type="journal" id="h0300"><person-group person-group-type="author"><name name-style="western"><surname>Rich</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Ching</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Lally</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Gaitanis</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Schwartzapfel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Charuvastra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Beckwith</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Flanigan</surname><given-names>T.P.</given-names></name></person-group><article-title>A review of the case for hepatitis B vaccination of high-risk adults</article-title><source>Am. J. Med.</source><volume>114</volume><year>2003</year><fpage>316</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1016/s0002-9343(02)01560-7</pub-id><pub-id pub-id-type="pmid">12681460</pub-id></element-citation></ref><ref id="b0305"><label>61</label><element-citation publication-type="journal" id="h0305"><person-group person-group-type="author"><name name-style="western"><surname>Soares</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cordeiro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Faneca</surname><given-names>H.</given-names></name><name name-style="western"><surname>Borges</surname><given-names>O.</given-names></name></person-group><article-title>Polymeric nanoengineered HBsAg DNA vaccine designed in combination with &#946;-glucan</article-title><source>Int. J. Biol. Macromol.</source><volume>122</volume><year>2019</year><fpage>930</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2018.11.024</pub-id><pub-id pub-id-type="pmid">30412757</pub-id></element-citation></ref><ref id="b0310"><label>62</label><element-citation publication-type="journal" id="h0310"><person-group person-group-type="author"><name name-style="western"><surname>Bos</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Kanellos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Crommelin</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Hennink</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Howard</surname><given-names>C.R.</given-names></name></person-group><article-title>Cationic polymers that enhance the performance of HbsAg DNA <italic toggle="yes">in vivo</italic></article-title><source>Vaccine</source><volume>23</volume><year>2004</year><fpage>460</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.06.020</pub-id><pub-id pub-id-type="pmid">15530694</pub-id></element-citation></ref><ref id="b0315"><label>63</label><element-citation publication-type="journal" id="h0315"><person-group person-group-type="author"><name name-style="western"><surname>Layek</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lipp</surname><given-names>L.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>J.</given-names></name></person-group><article-title>APC targeted micelle for enhanced intradermal delivery of hepatitis B DNA vaccine</article-title><source>J. Control. Release</source><volume>207</volume><year>2015</year><fpage>143</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2015.04.014</pub-id><pub-id pub-id-type="pmid">25886704</pub-id></element-citation></ref><ref id="b0320"><label>64</label><element-citation publication-type="journal" id="h0320"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Diao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X.</given-names></name></person-group><article-title>Astragalus polysaccharides enhance immune responses of HBV DNA vaccination <italic toggle="yes">via</italic> promoting the dendritic cell maturation and suppressing Treg frequency in mice</article-title><source>Int. Immunopharmacol.</source><volume>14</volume><year>2012</year><fpage>463</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2012.09.006</pub-id><pub-id pub-id-type="pmid">23006659</pub-id></element-citation></ref><ref id="b0325"><label>65</label><element-citation publication-type="journal" id="h0325"><person-group person-group-type="author"><name name-style="western"><surname>Chisari</surname><given-names>F.V.</given-names></name></person-group><article-title>Cytotoxic T cells and viral hepatitis</article-title><source>J. Clin. Invest.</source><volume>99</volume><year>1997</year><fpage>1472</fpage><lpage>1477</lpage><pub-id pub-id-type="doi">10.1172/jci119308</pub-id><pub-id pub-id-type="pmid">9119989</pub-id><pub-id pub-id-type="pmcid">PMC507965</pub-id></element-citation></ref><ref id="b0330"><label>66</label><element-citation publication-type="journal" id="h0330"><person-group person-group-type="author"><name name-style="western"><surname>Yoo</surname><given-names>Y.D.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.</given-names></name><name name-style="western"><surname>Flanders</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.I.</given-names></name><name name-style="western"><surname>Jay</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.J.</given-names></name></person-group><article-title>Regulation of transforming growth factor-&#946;1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis</article-title><source>J. Clin. Invest.</source><volume>97</volume><year>1996</year><fpage>388</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1172/jci118427</pub-id><pub-id pub-id-type="pmid">8567959</pub-id><pub-id pub-id-type="pmcid">PMC507029</pub-id></element-citation></ref><ref id="b0335"><label>67</label><element-citation publication-type="journal" id="h0335"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Reaney</surname><given-names>M.J.T.</given-names></name><name name-style="western"><surname>Shim</surname><given-names>Y.Y.</given-names></name></person-group><article-title>A flaxseed heteropolysaccharide stimulates immune responses and inhibits hepatitis B virus</article-title><source>Int. J. Biol. Macromol.</source><volume>136</volume><year>2019</year><fpage>230</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2019.06.076</pub-id><pub-id pub-id-type="pmid">31201916</pub-id></element-citation></ref><ref id="b0340"><label>68</label><element-citation publication-type="journal" id="h0340"><person-group person-group-type="author"><name name-style="western"><surname>Andrianov</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Fuerst</surname><given-names>T.R.</given-names></name></person-group><article-title>Immunopotentiating and delivery systems for HCV vaccines</article-title><source>Viruses</source><volume>13</volume><year>2021</year><object-id pub-id-type="publisher-id">981</object-id><pub-id pub-id-type="doi">10.3390/v13060981</pub-id><pub-id pub-id-type="pmcid">PMC8227888</pub-id><pub-id pub-id-type="pmid">34070543</pub-id></element-citation></ref><ref id="b0345"><label>69</label><element-citation publication-type="journal" id="h0345"><person-group person-group-type="author"><name name-style="western"><surname>Andrianov</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Marin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Karauzum</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agnihotri</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yunus</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Mariuzza</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Fuerst</surname><given-names>T.R.</given-names></name></person-group><article-title>Supramolecular assembly of toll-like receptor 7/8 agonist into multimeric water-soluble constructs enables superior immune stimulation <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic></article-title><source>ACS Appl. Bio Mater.</source><volume>3</volume><year>2020</year><fpage>3187</fpage><lpage>3195</lpage><pub-id pub-id-type="doi">10.1021/acsabm.0c00189</pub-id><pub-id pub-id-type="pmcid">PMC8054952</pub-id><pub-id pub-id-type="pmid">33880435</pub-id></element-citation></ref><ref id="b0350"><label>70</label><element-citation publication-type="journal" id="h0350"><person-group person-group-type="author"><name name-style="western"><surname>Andrianov</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Marin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fuerst</surname><given-names>T.R.</given-names></name></person-group><article-title>Molecular-level interactions of polyphosphazene immunoadjuvants and their potential role in antigen presentation and cell stimulation</article-title><source>Biomacromolecules</source><volume>17</volume><year>2016</year><fpage>3732</fpage><lpage>3742</lpage><pub-id pub-id-type="doi">10.1021/acs.biomac.6b01251</pub-id><pub-id pub-id-type="pmid">27748602</pub-id></element-citation></ref><ref id="b0355"><label>71</label><element-citation publication-type="journal" id="h0355"><person-group person-group-type="author"><name name-style="western"><surname>Andrianov</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Marin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agnihotri</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yunus</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Mariuzza</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Fuerst</surname><given-names>T.R.</given-names></name></person-group><article-title><italic toggle="yes">In vivo</italic> and <italic toggle="yes">in vitro</italic> potency of polyphosphazene immunoadjuvants with hepatitis C virus antigen and the role of their supramolecular assembly</article-title><source>Mol. Pharm.</source><volume>18</volume><year>2021</year><fpage>726</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.0c00487</pub-id><pub-id pub-id-type="pmid">32530637</pub-id><pub-id pub-id-type="pmcid">PMC7755742</pub-id></element-citation></ref><ref id="b0360"><label>72</label><element-citation publication-type="journal" id="h0360"><person-group person-group-type="author"><name name-style="western"><surname>Blattner</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Temin</surname><given-names>H.M.</given-names></name></person-group><article-title>HIV causes AIDS</article-title><source>Science</source><volume>241</volume><year>1988</year><fpage>515</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1126/science.3399881</pub-id><pub-id pub-id-type="pmid">3399881</pub-id></element-citation></ref><ref id="b0365"><label>73</label><element-citation publication-type="journal" id="h0365"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vasan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Ake</surname><given-names>J.A.</given-names></name></person-group><article-title>Current approaches to HIV vaccine development: A narrative review</article-title><source>J. Int. AIDS Soc.</source><volume>24</volume><year>2021</year><object-id pub-id-type="publisher-id">e25793</object-id><pub-id pub-id-type="doi">10.1002/jia2.25793</pub-id><pub-id pub-id-type="pmcid">PMC8606871</pub-id><pub-id pub-id-type="pmid">34806296</pub-id></element-citation></ref><ref id="b0370"><label>74</label><element-citation publication-type="journal" id="h0370"><person-group person-group-type="author"><name name-style="western"><surname>Toledo</surname><given-names>N.P.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Omange</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Dacoba</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Crecente-Campo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Whitney</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Plummer</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Cervico-vaginal inflammatory cytokine and chemokine responses to two different SIV immunogens</article-title><source>Front. Immunol.</source><volume>11</volume><year>2020</year><object-id pub-id-type="publisher-id">1935</object-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.01935</pub-id><pub-id pub-id-type="pmcid">PMC7477078</pub-id><pub-id pub-id-type="pmid">32983121</pub-id></element-citation></ref><ref id="b0375"><label>75</label><element-citation publication-type="journal" id="h0375"><person-group person-group-type="author"><name name-style="western"><surname>Francica</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Laga</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lynn</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Mu&#382;&#237;kov&#225;</surname><given-names>G.</given-names></name><name name-style="western"><surname>Androvi&#269;</surname><given-names>L.</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>K.O.</given-names></name><name name-style="western"><surname>Baharom</surname><given-names>F.</given-names></name><name name-style="western"><surname>Petrovas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Seder</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates</article-title><source>PLoS Biol.</source><volume>17</volume><year>2019</year><object-id pub-id-type="publisher-id">e3000328</object-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3000328</pub-id><pub-id pub-id-type="pmcid">PMC6597128</pub-id><pub-id pub-id-type="pmid">31206510</pub-id></element-citation></ref><ref id="b0380"><label>76</label><element-citation publication-type="journal" id="h0380"><person-group person-group-type="author"><name name-style="western"><surname>Dacoba</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Omange</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Crecente-Campo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>M.J.</given-names></name></person-group><article-title>Polysaccharide nanoparticles can efficiently modulate the immune response against an HIV peptide antigen</article-title><source>ACS Nano</source><volume>13</volume><year>2019</year><fpage>4947</fpage><lpage>4959</lpage><pub-id pub-id-type="doi">10.1021/acsnano.8b07662</pub-id><pub-id pub-id-type="pmid">30964270</pub-id><pub-id pub-id-type="pmcid">PMC6607401</pub-id></element-citation></ref><ref id="b0385"><label>77</label><element-citation publication-type="journal" id="h0385"><person-group person-group-type="author"><name name-style="western"><surname>Hussein</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Skwarczynski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Toth</surname><given-names>I.</given-names></name></person-group><article-title>Toll-like receptor agonists: A patent review (2011&#8211;2013)</article-title><source>Expert Opin. Ther. Pat.</source><volume>24</volume><year>2014</year><fpage>453</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1517/13543776.2014.880691</pub-id><pub-id pub-id-type="pmid">24456079</pub-id></element-citation></ref><ref id="b0390"><label>78</label><element-citation publication-type="journal" id="h0390"><person-group person-group-type="author"><name name-style="western"><surname>Liong</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A.A.A.</given-names></name><name name-style="western"><surname>Mann</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Gale</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Maikawa</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Appel</surname><given-names>E.A.</given-names></name></person-group><article-title>Enhanced humoral immune response by high density TLR agonist presentation on hyperbranched polymers</article-title><source>Adv. Ther.</source><volume>4</volume><year>2021</year><object-id pub-id-type="publisher-id">2000081</object-id><pub-id pub-id-type="doi">10.1002/adtp.202000081</pub-id></element-citation></ref><ref id="b0395"><label>79</label><element-citation publication-type="journal" id="h0395"><person-group person-group-type="author"><name name-style="western"><surname>Boopathy</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Mandal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kulp</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Menis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Thai</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Schief</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Hammond</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Irvine</surname><given-names>D.J.</given-names></name></person-group><article-title>Enhancing humoral immunity <italic toggle="yes">via</italic> sustained-release implantable microneedle patch vaccination</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>116</volume><year>2019</year><fpage>16473</fpage><lpage>16478</lpage><pub-id pub-id-type="doi">10.1073/pnas.1902179116</pub-id><pub-id pub-id-type="pmid">31358641</pub-id><pub-id pub-id-type="pmcid">PMC6697788</pub-id></element-citation></ref><ref id="b0400"><label>80</label><element-citation publication-type="journal" id="h0400"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>W.</given-names></name></person-group><article-title>Engineering a &#8220;PEG-<italic toggle="yes">g</italic>-PEI/DNA nanoparticle-in- PLGA microsphere&#8221; hybrid controlled release system to enhance immunogenicity of DNA vaccine</article-title><source>Mater. Sci. Eng. C Mater. Biol. Appl.</source><volume>106</volume><year>2020</year><object-id pub-id-type="publisher-id">110294</object-id><pub-id pub-id-type="doi">10.1016/j.msec.2019.110294</pub-id><pub-id pub-id-type="pmid">31753340</pub-id></element-citation></ref><ref id="b0405"><label>81</label><element-citation publication-type="journal" id="h0405"><person-group person-group-type="author"><name name-style="western"><surname>Vidya Vijayan</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Karthigeyan</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Hanna</surname><given-names>L.E.</given-names></name></person-group><article-title>Pathophysiology of CD4<sup>+</sup> T-cell depletion in HIV-1 and HIV-2 infections</article-title><source>Front. Immunol.</source><volume>8</volume><year>2017</year><object-id pub-id-type="publisher-id">580</object-id><pub-id pub-id-type="doi">10.3389/fimmu.2017.00580</pub-id><pub-id pub-id-type="pmcid">PMC5440548</pub-id><pub-id pub-id-type="pmid">28588579</pub-id></element-citation></ref><ref id="b0410"><label>82</label><element-citation publication-type="journal" id="h0410"><person-group person-group-type="author"><name name-style="western"><surname>Ondondo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Murakoshi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Clutton</surname><given-names>G.</given-names></name><name name-style="western"><surname>Abdul-Jawad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wee</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Gatanaga</surname><given-names>H.</given-names></name><name name-style="western"><surname>Oka</surname><given-names>S.</given-names></name><name name-style="western"><surname>McMichael</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Takiguchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Korber</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hanke</surname><given-names>T.</given-names></name></person-group><article-title>Novel conserved-region T-cell mosaic vaccine with high global HIV-1 coverage is recognized by protective responses in untreated infection</article-title><source>Mol. Ther.</source><volume>24</volume><year>2016</year><fpage>832</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1038/mt.2016.3</pub-id><pub-id pub-id-type="pmid">26743582</pub-id><pub-id pub-id-type="pmcid">PMC4886941</pub-id></element-citation></ref><ref id="b0415"><label>83</label><element-citation publication-type="journal" id="h0415"><person-group person-group-type="author"><name name-style="western"><surname>Moyo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Buus</surname><given-names>S.</given-names></name><name name-style="western"><surname>Erbar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wee</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Sahin</surname><given-names>U.</given-names></name><name name-style="western"><surname>Hanke</surname><given-names>T.</given-names></name></person-group><article-title>Efficient induction of T cells against conserved HIV-1 regions by mosaic vaccines delivered as self-amplifying mRNA</article-title><source>Mol. Ther. Methods Clin. Dev.</source><volume>12</volume><year>2019</year><fpage>32</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.omtm.2018.10.010</pub-id><pub-id pub-id-type="pmid">30547051</pub-id><pub-id pub-id-type="pmcid">PMC6258890</pub-id></element-citation></ref><ref id="b0420"><label>84</label><element-citation publication-type="journal" id="h0420"><person-group person-group-type="author"><name name-style="western"><surname>Ng'uni</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chasara</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ndhlovu</surname><given-names>Z.M.</given-names></name></person-group><article-title>Major scientific hurdles in HIV vaccine development: Historical perspective and future directions</article-title><source>Front. Immunol.</source><volume>11</volume><year>2020</year><object-id pub-id-type="publisher-id">590780</object-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.590780</pub-id><pub-id pub-id-type="pmcid">PMC7655734</pub-id><pub-id pub-id-type="pmid">33193428</pub-id></element-citation></ref><ref id="b0425"><label>85</label><element-citation publication-type="journal" id="h0425"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yue</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.L.</given-names></name></person-group><article-title>Prophylactic vaccine delivery systems against epidemic infectious diseases</article-title><source>Adv. Drug Deliv. Rev.</source><volume>176</volume><year>2021</year><object-id pub-id-type="publisher-id">113867</object-id><pub-id pub-id-type="doi">10.1016/j.addr.2021.113867</pub-id><pub-id pub-id-type="pmcid">PMC8285224</pub-id><pub-id pub-id-type="pmid">34280513</pub-id></element-citation></ref><ref id="b0430"><label>86</label><element-citation publication-type="journal" id="h0430"><person-group person-group-type="author"><name name-style="western"><surname>Kirtane</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Karandikar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Furin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Traverso</surname><given-names>G.</given-names></name></person-group><article-title>Nanotechnology approaches for global infectious diseases</article-title><source>Nat. Nanotechnol.</source><volume>16</volume><year>2021</year><fpage>369</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1038/s41565-021-00866-8</pub-id><pub-id pub-id-type="pmid">33753915</pub-id></element-citation></ref><ref id="b0435"><label>87</label><element-citation publication-type="journal" id="h0435"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>Antiviral biomaterials</article-title><source>Matter</source><volume>4</volume><year>2021</year><fpage>1892</fpage><lpage>1918</lpage><pub-id pub-id-type="doi">10.1016/j.matt.2021.03.016</pub-id></element-citation></ref><ref id="b0440"><label>88</label><element-citation publication-type="journal" id="h0440"><person-group person-group-type="author"><name name-style="western"><surname>Hirth</surname><given-names>J.</given-names></name></person-group><article-title>Disparities in HPV vaccination rates and HPV prevalence in the United States: A review of the literature</article-title><source>Hum. Vaccin. Immunother.</source><volume>15</volume><year>2019</year><fpage>146</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1080/21645515.2018.1512453</pub-id><pub-id pub-id-type="pmid">30148974</pub-id><pub-id pub-id-type="pmcid">PMC6363146</pub-id></element-citation></ref><ref id="b0445"><label>89</label><element-citation publication-type="journal" id="h0445"><person-group person-group-type="author"><name name-style="western"><surname>Zhai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tumban</surname><given-names>E.</given-names></name></person-group><article-title>Gardasil-9: A global survey of projected efficacy</article-title><source>Antiviral Res.</source><volume>130</volume><year>2016</year><fpage>101</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.03.016</pub-id><pub-id pub-id-type="pmid">27040313</pub-id></element-citation></ref><ref id="b0450"><label>90</label><element-citation publication-type="journal" id="h0450"><person-group person-group-type="author"><name name-style="western"><surname>Reagan-Steiner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yankey</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jeyarajah</surname><given-names>J.</given-names></name><name name-style="western"><surname>Elam-Evans</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Singleton</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>MacNeil</surname><given-names>J.</given-names></name><name name-style="western"><surname>Markowitz</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Stokley</surname><given-names>S.</given-names></name></person-group><article-title>National, regional, state, and selected local area vaccination coverage among adolescents aged 13&#8211;17 years&#8212;United States, 2014</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><volume>64</volume><year>2015</year><fpage>784</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6429a3</pub-id><pub-id pub-id-type="pmid">26225476</pub-id><pub-id pub-id-type="pmcid">PMC4584833</pub-id></element-citation></ref><ref id="b0455"><label>91</label><element-citation publication-type="journal" id="h0455"><person-group person-group-type="author"><name name-style="western"><surname>Shao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ortega-Rivera</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pokorski</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>N.F.</given-names></name></person-group><article-title>A scalable manufacturing approach to single dose vaccination against HPV</article-title><source>Vaccines</source><volume>9</volume><year>2021</year><object-id pub-id-type="publisher-id">66</object-id><pub-id pub-id-type="doi">10.3390/vaccines9010066</pub-id><pub-id pub-id-type="pmcid">PMC7835769</pub-id><pub-id pub-id-type="pmid">33478147</pub-id></element-citation></ref><ref id="b0460"><label>92</label><element-citation publication-type="journal" id="h0460"><person-group person-group-type="author"><name name-style="western"><surname>Valencia</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Zacharia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>C.</given-names></name><name name-style="western"><surname>Difilippantonio</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kirnbauer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Roden</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Shoemaker</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Andrianov</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>J.D.</given-names></name></person-group><article-title>Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP</article-title><source>Hum. Vaccin. Immunother.</source><volume>17</volume><year>2021</year><fpage>2748</fpage><lpage>2761</lpage><pub-id pub-id-type="doi">10.1080/21645515.2021.1875763</pub-id><pub-id pub-id-type="pmid">33573433</pub-id><pub-id pub-id-type="pmcid">PMC8475605</pub-id></element-citation></ref><ref id="b0465"><label>93</label><element-citation publication-type="journal" id="h0465"><person-group person-group-type="author"><name name-style="western"><surname>Marin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>A.</given-names></name><name name-style="western"><surname>Valencia</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Zacharia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kirnbauer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Roden</surname><given-names>R.B.S.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Shoemaker</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Andrianov</surname><given-names>A.K.</given-names></name></person-group><article-title>Next generation polyphosphazene immunoadjuvant: Synthesis, self-assembly and <italic toggle="yes">in vivo</italic> potency with human papillomavirus VLPs-based vaccine</article-title><source>Nanomedicine</source><volume>33</volume><year>2021</year><object-id pub-id-type="publisher-id">102359</object-id><pub-id pub-id-type="doi">10.1016/j.nano.2021.102359</pub-id><pub-id pub-id-type="pmcid">PMC8184581</pub-id><pub-id pub-id-type="pmid">33476764</pub-id></element-citation></ref><ref id="b0470"><label>94</label><element-citation publication-type="journal" id="h0470"><person-group person-group-type="author"><name name-style="western"><surname>Malvy</surname><given-names>D.</given-names></name><name name-style="western"><surname>McElroy</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>de Clerck</surname><given-names>H.</given-names></name><name name-style="western"><surname>G&#252;nther</surname><given-names>S.</given-names></name><name name-style="western"><surname>van Griensven</surname><given-names>J.</given-names></name></person-group><article-title>Ebola virus disease</article-title><source>Lancet</source><volume>393</volume><year>2019</year><fpage>936</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(18)33132-5</pub-id><pub-id pub-id-type="pmid">30777297</pub-id></element-citation></ref><ref id="b0475"><label>95</label><element-citation publication-type="journal" id="h0475"><person-group person-group-type="author"><name name-style="western"><surname>Thom</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tipton</surname><given-names>T.</given-names></name><name name-style="western"><surname>Strecker</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Akoi Bore</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sakoba</surname><given-names>K.</given-names></name><name name-style="western"><surname>Magassouba</surname><given-names>N.</given-names></name><name name-style="western"><surname>G&#252;nther</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kader Konde</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>M.W.</given-names></name><etal/></person-group><article-title>Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: An observational cohort study</article-title><source>Lancet Infect. Dis.</source><volume>21</volume><year>2021</year><fpage>507</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1016/s1473-3099(20)30736-2</pub-id><pub-id pub-id-type="pmid">33065039</pub-id><pub-id pub-id-type="pmcid">PMC7553754</pub-id></element-citation></ref><ref id="b0480"><label>96</label><element-citation publication-type="journal" id="h0480"><person-group person-group-type="author"><name name-style="western"><surname>Karpenko</surname><given-names>L.I.</given-names></name><name name-style="western"><surname>Apartsin</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Dudko</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Starostina</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Kaplina</surname><given-names>O.N.</given-names></name><name name-style="western"><surname>Zaitsev</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Bakulina</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Venyaminova</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Ilyichev</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Bazhan</surname><given-names>S.I.</given-names></name><etal/></person-group><article-title>Cationic polymers for the delivery of the Ebola DNA vaccine encoding artificial T-cell immunogen</article-title><source>Vaccines</source><volume>8</volume><year>2020</year><object-id pub-id-type="publisher-id">718</object-id><pub-id pub-id-type="doi">10.3390/vaccines8040718</pub-id><pub-id pub-id-type="pmcid">PMC7760684</pub-id><pub-id pub-id-type="pmid">33271964</pub-id></element-citation></ref><ref id="b0485"><label>97</label><element-citation publication-type="journal" id="h0485"><person-group person-group-type="author"><name name-style="western"><surname>Hosseini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oliva-Ram&#237;rez</surname><given-names>J.</given-names></name><name name-style="western"><surname>V&#225;zquez-Villegas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rodriguez-Garcia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mu&#241;oz-Soto</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Aghamohammadi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Martinez-Chapa</surname><given-names>S.O.</given-names></name></person-group><article-title>Dengue fever: A worldwide threat an overview of the infection process, environmental factors for a global outbreak, diagnostic platforms and vaccine developments</article-title><source>Curr. Top Med. Chem.</source><volume>18</volume><year>2018</year><fpage>1531</fpage><lpage>1549</lpage><pub-id pub-id-type="doi">10.2174/1568026618666181105130000</pub-id><pub-id pub-id-type="pmid">30394209</pub-id></element-citation></ref><ref id="b0490"><label>98</label><element-citation publication-type="journal" id="h0490"><person-group person-group-type="author"><name name-style="western"><surname>Khetarpal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>I.</given-names></name></person-group><article-title>Dengue fever: Causes, complications, and vaccine strategies</article-title><source>J. Immunol. Res.</source><volume>2016</volume><year>2016</year><object-id pub-id-type="publisher-id">6803098</object-id><pub-id pub-id-type="doi">10.1155/2016/6803098</pub-id><pub-id pub-id-type="pmcid">PMC4971387</pub-id><pub-id pub-id-type="pmid">27525287</pub-id></element-citation></ref><ref id="b0495"><label>99</label><element-citation publication-type="journal" id="h0495"><person-group person-group-type="author"><name name-style="western"><surname>Halstead</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Katzelnick</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Markoff</surname><given-names>L.</given-names></name><name name-style="western"><surname>Aguiar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dans</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Dans</surname><given-names>A.L.</given-names></name></person-group><article-title>Ethics of a partially effective dengue vaccine: Lessons from the Philippines</article-title><source>Vaccine</source><volume>38</volume><year>2020</year><fpage>5572</fpage><lpage>5576</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.06.079</pub-id><pub-id pub-id-type="pmid">32654899</pub-id><pub-id pub-id-type="pmcid">PMC7347470</pub-id></element-citation></ref><ref id="b0500"><label>100</label><element-citation publication-type="journal" id="h0500"><person-group person-group-type="author"><name name-style="western"><surname>Rodgers</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Cordeiro</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Kissenpfennig</surname><given-names>A.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>R.F.</given-names></name></person-group><article-title>Microneedle arrays for vaccine delivery: The possibilities, challenges and use of nanoparticles as a combinatorial approach for enhanced vaccine immunogenicity</article-title><source>Expert Opin. Drug Deliv.</source><volume>15</volume><year>2018</year><fpage>851</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1080/17425247.2018.1505860</pub-id><pub-id pub-id-type="pmid">30051726</pub-id></element-citation></ref><ref id="b0505"><label>101</label><element-citation publication-type="journal" id="h0505"><person-group person-group-type="author"><name name-style="western"><surname>Uppu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Turvey</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Sharif</surname><given-names>A.R.M.</given-names></name><name name-style="western"><surname>Bidet</surname><given-names>K.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>V.</given-names></name><name name-style="western"><surname>Tambe</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Lescar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>E.Y.</given-names></name><name name-style="western"><surname>Fink</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hammond</surname><given-names>P.T.</given-names></name></person-group><article-title>Temporal release of a three-component protein subunit vaccine from polymer multilayers</article-title><source>J. Control. Release</source><volume>317</volume><year>2020</year><fpage>130</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2019.11.022</pub-id><pub-id pub-id-type="pmid">31756392</pub-id></element-citation></ref><ref id="b0510"><label>102</label><element-citation publication-type="journal" id="h0510"><person-group person-group-type="author"><name name-style="western"><surname>Baud</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gubler</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Schaub</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lanteri</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Musso</surname><given-names>D.</given-names></name></person-group><article-title>An update on Zika virus infection</article-title><source>Lancet</source><volume>390</volume><year>2017</year><fpage>2099</fpage><lpage>2109</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(17)31450-2</pub-id><pub-id pub-id-type="pmid">28647173</pub-id></element-citation></ref><ref id="b0515"><label>103</label><element-citation publication-type="journal" id="h0515"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name></person-group><article-title>Advances in aluminum hydroxide-based adjuvant research and its mechanism</article-title><source>Hum. Vaccin. Immunother.</source><volume>11</volume><year>2015</year><fpage>477</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1080/21645515.2014.1004026</pub-id><pub-id pub-id-type="pmid">25692535</pub-id><pub-id pub-id-type="pmcid">PMC4514166</pub-id></element-citation></ref><ref id="b0520"><label>104</label><element-citation publication-type="journal" id="h0520"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.H.</given-names></name></person-group><article-title>Potential Zika vaccine: Encapsulated nanocomplex promotes both T<sub>H</sub>1/T<sub>H</sub>2 responses in mice</article-title><source>Adv. Ther.</source><volume>3</volume><year>2020</year><object-id pub-id-type="publisher-id">1900197</object-id><pub-id pub-id-type="doi">10.1002/adtp.201900197</pub-id></element-citation></ref><ref id="b0525"><label>105</label><element-citation publication-type="journal" id="h0525"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Whitney</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pilishvili</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dooling</surname><given-names>K.L.</given-names></name></person-group><article-title>Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: Recommendations of the advisory committee on immunization practices (ACIP)</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><volume>61</volume><year>2012</year><fpage>816</fpage><lpage>819</lpage><pub-id pub-id-type="pmid">23051612</pub-id></element-citation></ref><ref id="b0530"><label>106</label><element-citation publication-type="journal" id="h0530"><person-group person-group-type="author"><name name-style="western"><surname>Ritz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hanekom</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Robins-Browne</surname><given-names>R.</given-names></name><name name-style="western"><surname>Britton</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>N.</given-names></name></person-group><article-title>Influence of BCG vaccine strain on the immune response and protection against tuberculosis</article-title><source>FEMS Microbiol. Rev.</source><volume>32</volume><year>2008</year><fpage>821</fpage><lpage>841</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6976.2008.00118.x</pub-id><pub-id pub-id-type="pmid">18616602</pub-id></element-citation></ref><ref id="b0535"><label>107</label><element-citation publication-type="journal" id="h0535"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>F.T.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name></person-group><article-title>Protective immune responses elicited by fusion protein containing PsaA and PspA fragments</article-title><source>Immunol. Invest.</source><volume>44</volume><year>2015</year><fpage>482</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.3109/08820139.2015.1037956</pub-id><pub-id pub-id-type="pmid">26107747</pub-id></element-citation></ref><ref id="b0540"><label>108</label><element-citation publication-type="journal" id="h0540"><person-group person-group-type="author"><name name-style="western"><surname>Robla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Prasanna</surname><given-names>M.</given-names></name><name name-style="western"><surname>Varela-Calvino</surname><given-names>R.</given-names></name><name name-style="western"><surname>Grandjean</surname><given-names>C.</given-names></name><name name-style="western"><surname>Csaba</surname><given-names>N.</given-names></name></person-group><article-title>A chitosan-based nanosystem as pneumococcal vaccine delivery platform</article-title><source>Drug Deliv. Transl. Res.</source><volume>11</volume><year>2021</year><fpage>581</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1007/s13346-021-00928-3</pub-id><pub-id pub-id-type="pmid">33655441</pub-id></element-citation></ref><ref id="b0545"><label>109</label><element-citation publication-type="journal" id="h0545"><person-group person-group-type="author"><name name-style="western"><surname>Yuki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sawada</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Nakahashi-Ouchida</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sugiura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kurokawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mukerji</surname><given-names>R.</given-names></name><name name-style="western"><surname>Briles</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Akiyoshi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kiyono</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Characterization and specification of a trivalent protein-based pneumococcal vaccine formulation using an adjuvant-free nanogel nasal delivery system</article-title><source>Mol. Biopharm.</source><volume>18</volume><year>2021</year><fpage>1582</fpage><lpage>1592</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.0c01003</pub-id><pub-id pub-id-type="pmid">33621107</pub-id></element-citation></ref><ref id="b0550"><label>110</label><element-citation publication-type="journal" id="h0550"><person-group person-group-type="author"><name name-style="western"><surname>Nakahashi-Ouchida</surname><given-names>R.</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yuki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Katakai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yamanoue</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mukerji</surname><given-names>R.</given-names></name><name name-style="western"><surname>Briles</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Yasutomi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Akiyoshi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kiyono</surname><given-names>H.</given-names></name><etal/></person-group><article-title>A nanogel-based trivalent PspA nasal vaccine protects macaques from intratracheal challenge with pneumococci</article-title><source>Vaccine</source><volume>39</volume><year>2021</year><fpage>3353</fpage><lpage>3364</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.04.069</pub-id><pub-id pub-id-type="pmid">34016473</pub-id></element-citation></ref><ref id="b0555"><label>111</label><element-citation publication-type="journal" id="h0555"><person-group person-group-type="author"><name name-style="western"><surname>Fukuyama</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yuki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Katakai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Harada</surname><given-names>N.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Briles</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Yasutomi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tsukada</surname><given-names>H.</given-names></name><name name-style="western"><surname>Akiyoshi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kiyono</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Nanogel-based pneumococcal surface protein A nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against streptococcus pneumoniae in macaques</article-title><source>Mucosal Immunol.</source><volume>8</volume><year>2015</year><fpage>1144</fpage><lpage>1153</lpage><pub-id pub-id-type="doi">10.1038/mi.2015.5</pub-id><pub-id pub-id-type="pmid">25669148</pub-id><pub-id pub-id-type="pmcid">PMC4762909</pub-id></element-citation></ref><ref id="b0560"><label>112</label><element-citation publication-type="journal" id="h0560"><person-group person-group-type="author"><name name-style="western"><surname>Boeckler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Frisch</surname><given-names>B.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schuber</surname><given-names>F.</given-names></name></person-group><article-title>Immunogenicity of new heterobifunctional cross-linking reagents used in the conjugation of synthetic peptides to liposomes</article-title><source>J. Immunol. Methods</source><volume>191</volume><year>1996</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/0022-1759(95)00284-7</pub-id><pub-id pub-id-type="pmid">8642195</pub-id></element-citation></ref><ref id="b0565"><label>113</label><element-citation publication-type="journal" id="h0565"><person-group person-group-type="author"><name name-style="western"><surname>Palaniappan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>U.P.</given-names></name><name name-style="western"><surname>Sakthivel</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Ades</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Briles</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Hollingshead</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Paton</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Sampson</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Lillard</surname><given-names>J.W.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Differential PsaA-, PspA-, PspC-, and PdB-specific immune responses in a mouse model of pneumococcal carriage</article-title><source>Infect. Immun.</source><volume>73</volume><year>2005</year><fpage>1006</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.1128/iai.73.2.1006-1013.2005</pub-id><pub-id pub-id-type="pmid">15664944</pub-id><pub-id pub-id-type="pmcid">PMC547096</pub-id></element-citation></ref><ref id="b0570"><label>114</label><element-citation publication-type="journal" id="h0570"><person-group person-group-type="author"><name name-style="western"><surname>Schrager</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Vekemens</surname><given-names>J.</given-names></name><name name-style="western"><surname>Drager</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lewinsohn</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Olesen</surname><given-names>O.F.</given-names></name></person-group><article-title>The status of tuberculosis vaccine development</article-title><source>Lancet Infect. Dis.</source><volume>20</volume><year>2020</year><fpage>e28</fpage><lpage>e37</lpage><pub-id pub-id-type="doi">10.1016/s1473-3099(19)30625-5</pub-id><pub-id pub-id-type="pmid">32014117</pub-id></element-citation></ref><ref id="b0575"><label>115</label><element-citation publication-type="journal" id="h0575"><person-group person-group-type="author"><name name-style="western"><surname>Zare</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kabiri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Amini</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Najafi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mohammadpour</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ayati</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Nikpoor</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Tafaghodi</surname><given-names>M.</given-names></name></person-group><article-title>Immunological assessment of chitosan or trimethyl chitosan-coated PLGA nanospheres containing fusion antigen as the novel vaccine candidates against Tuberculosis</article-title><source>AAPS PharmSciTech</source><volume>23</volume><year>2021</year><fpage>15</fpage><pub-id pub-id-type="doi">10.1208/s12249-021-02146-z</pub-id><pub-id pub-id-type="pmid">34893923</pub-id></element-citation></ref><ref id="b0580"><label>116</label><element-citation publication-type="journal" id="h0580"><person-group person-group-type="author"><name name-style="western"><surname>van der Lubben</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Verhoef</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Borchard</surname><given-names>G.</given-names></name><name name-style="western"><surname>Junginger</surname><given-names>H.E.</given-names></name></person-group><article-title>Chitosan for mucosal vaccination</article-title><source>Adv. Drug Deliver. Rev.</source><volume>52</volume><year>2001</year><fpage>139</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/s0169-409x(01)00197-1</pub-id><pub-id pub-id-type="pmid">11718937</pub-id></element-citation></ref><ref id="b0585"><label>117</label><element-citation publication-type="journal" id="h0585"><person-group person-group-type="author"><name name-style="western"><surname>Diego-Gonzalez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Crecente-Campo</surname><given-names>J.</given-names></name><name name-style="western"><surname>John Paul</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reljic</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jose Alonso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gonzalez-Fernandez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Simon-Vazquez</surname><given-names>R.</given-names></name></person-group><article-title>Design of polymeric nanocapsules for intranasal vaccination against mycobacterium Tuberculosis: Influence of the polymeric shell and antigen positioning</article-title><source>Pharmaceutics</source><volume>12</volume><year>2020</year><object-id pub-id-type="publisher-id">489</object-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12060489</pub-id><pub-id pub-id-type="pmcid">PMC7355676</pub-id><pub-id pub-id-type="pmid">32481601</pub-id></element-citation></ref><ref id="b0590"><label>118</label><element-citation publication-type="journal" id="h0590"><person-group person-group-type="author"><name name-style="western"><surname>Sl&#252;tter</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Keijzer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mallants</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hagenaars</surname><given-names>N.</given-names></name><name name-style="western"><surname>Que</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kaijzel</surname><given-names>E.</given-names></name><name name-style="western"><surname>van Eden</surname><given-names>W.</given-names></name><name name-style="western"><surname>Augustijns</surname><given-names>P.</given-names></name><name name-style="western"><surname>L&#246;wik</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bouwstra</surname><given-names>J.</given-names></name><name name-style="western"><surname>Broere</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W.</given-names></name></person-group><article-title>Nasal vaccination with <italic toggle="yes">N</italic>-trimethyl chitosan and PLGA based nanoparticles: Nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen</article-title><source>Vaccine</source><volume>28</volume><year>2010</year><fpage>6282</fpage><lpage>6291</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.06.121</pub-id><pub-id pub-id-type="pmid">20638455</pub-id></element-citation></ref><ref id="b0595"><label>119</label><element-citation publication-type="journal" id="h0595"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sandford</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kirman</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>B.H.A.</given-names></name></person-group><article-title>Innovative antigen carrier system for the development of tuberculosis vaccines</article-title><source>FASEB J.</source><volume>33</volume><year>2019</year><fpage>7505</fpage><lpage>7518</lpage><pub-id pub-id-type="doi">10.1096/fj.201802501RR</pub-id><pub-id pub-id-type="pmid">30870010</pub-id></element-citation></ref><ref id="b0600"><label>120</label><element-citation publication-type="journal" id="h0600"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Quan</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.T.</given-names></name><name name-style="western"><surname>Sandford</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kirman</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Britton</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>B.H.A.</given-names></name></person-group><article-title>Particulate mycobacterial vaccines induce protective immunity against Tuberculosis in mice</article-title><source>Nanomaterials</source><volume>11</volume><year>2021</year><object-id pub-id-type="publisher-id">2060</object-id><pub-id pub-id-type="doi">10.3390/nano11082060</pub-id><pub-id pub-id-type="pmcid">PMC8402087</pub-id><pub-id pub-id-type="pmid">34443891</pub-id></element-citation></ref><ref id="b0605"><label>121</label><element-citation publication-type="journal" id="h0605"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Parlane</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>B.H.A.</given-names></name><name name-style="western"><surname>Buddle</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Heiser</surname><given-names>A.</given-names></name></person-group><article-title>Engineering mycobacteria for the production of self-assembling biopolyesters displaying mycobacterial antigens for use as a Tuberculosis vaccine</article-title><source>Appl. Environ. Microbiol.</source><volume>83</volume><year>2017</year><object-id pub-id-type="publisher-id">e02289-16</object-id><pub-id pub-id-type="doi">10.1128/aem.02289-16</pub-id><pub-id pub-id-type="pmcid">PMC5311400</pub-id><pub-id pub-id-type="pmid">28087528</pub-id></element-citation></ref><ref id="b0610"><label>122</label><element-citation publication-type="journal" id="h0610"><person-group person-group-type="author"><name name-style="western"><surname>Belotserkovsky</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sansonetti</surname><given-names>P.J.</given-names></name></person-group><article-title><italic toggle="yes">Shigella</italic> and enteroinvasive <italic toggle="yes">Escherichia coli</italic></article-title><source>Curr. Top. Microbiol. Immunol.</source><volume>416</volume><year>2018</year><fpage>1</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1007/82_2018_104</pub-id><pub-id pub-id-type="pmid">30218158</pub-id></element-citation></ref><ref id="b0615"><label>123</label><element-citation publication-type="journal" id="h0615"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Ryan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vidal</surname><given-names>R.</given-names></name><name name-style="western"><surname>del Canto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Carlos Salazar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Montero</surname><given-names>D.</given-names></name></person-group><article-title>Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for <italic toggle="yes">Shigella</italic>, <italic toggle="yes">Salmonella</italic>, enterotoxigenic <italic toggle="yes">E. coli</italic> (ETEC) enterohemorragic <italic toggle="yes">E. coli</italic> (EHEC) and campylobacter jejuni</article-title><source>Hum. Vaccin. Immunother.</source><volume>11</volume><year>2015</year><fpage>601</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1080/21645515.2015.1011578</pub-id><pub-id pub-id-type="pmid">25715096</pub-id><pub-id pub-id-type="pmcid">PMC4514228</pub-id></element-citation></ref><ref id="b0620"><label>124</label><element-citation publication-type="journal" id="h0620"><person-group person-group-type="author"><name name-style="western"><surname>Nataro</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Kaper</surname><given-names>J.B.</given-names></name></person-group><article-title>Diarrheagenic <italic toggle="yes">Escherichia coli</italic></article-title><source>Clin. Microbiol. Rev.</source><volume>11</volume><year>1998</year><fpage>142</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1128/cmr.11.1.142</pub-id><pub-id pub-id-type="pmid">9457432</pub-id><pub-id pub-id-type="pmcid">PMC121379</pub-id></element-citation></ref><ref id="b0625"><label>125</label><element-citation publication-type="journal" id="h0625"><person-group person-group-type="author"><name name-style="western"><surname>Khanifar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Kazemi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ramandi</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Amani</surname><given-names>J.</given-names></name><name name-style="western"><surname>Salmanian</surname><given-names>A.H.</given-names></name></person-group><article-title>Prevention of EHEC infection by chitosan nano-structure coupled with synthetic recombinant antigen</article-title><source>J. Microbiol. Methods</source><volume>157</volume><year>2019</year><fpage>100</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.mimet.2019.01.002</pub-id><pub-id pub-id-type="pmid">30633949</pub-id></element-citation></ref><ref id="b0630"><label>126</label><element-citation publication-type="journal" id="h0630"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Vishakante</surname><given-names>G.D.</given-names></name></person-group><article-title>Development and evaluation of porous chitosan nanoparticles for treatment of enterotoxigenic <italic toggle="yes">Escherichia coil</italic> infection</article-title><source>J. Biomed. Nanotechnol.</source><volume>9</volume><year>2013</year><fpage>107</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1166/jbn.2013.1471</pub-id><pub-id pub-id-type="pmid">23627073</pub-id></element-citation></ref><ref id="b0635"><label>127</label><element-citation publication-type="journal" id="h0635"><person-group person-group-type="author"><name name-style="western"><surname>Nazarian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gargari</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Rasooli</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hasannia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pirooznia</surname><given-names>N.</given-names></name></person-group><article-title>A PLGA-encapsulated chimeric protein protects against adherence and toxicity of enterotoxigenic <italic toggle="yes">Escherichia coli</italic></article-title><source>Microbiol. Res.</source><volume>169</volume><year>2014</year><fpage>205</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/j.micres.2013.06.005</pub-id><pub-id pub-id-type="pmid">23906742</pub-id></element-citation></ref><ref id="b0640"><label>128</label><element-citation publication-type="journal" id="h0640"><person-group person-group-type="author"><name name-style="western"><surname>Byrd</surname><given-names>W.</given-names></name><name name-style="western"><surname>de Lorimier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z.R.</given-names></name><name name-style="western"><surname>Cassels</surname><given-names>F.J.</given-names></name></person-group><article-title>Microencapsulated subunit vaccine approach to enterotoxigenic <italic toggle="yes">Escherichia coli</italic> and other mucosal pathogens</article-title><source>Adv. Drug Deliv. Rev.</source><volume>57</volume><year>2005</year><fpage>1362</fpage><lpage>1380</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2005.01.014</pub-id><pub-id pub-id-type="pmid">15935878</pub-id></element-citation></ref><ref id="b0645"><label>129</label><element-citation publication-type="journal" id="h0645"><person-group person-group-type="author"><name name-style="western"><surname>Ghaffari Marandi</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Zolfaghari</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Kazemi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Motamedi</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Amani</surname><given-names>J.</given-names></name></person-group><article-title>Immunization against <italic toggle="yes">Vibrio cholerae</italic>, ETEC, and EHEC with chitosan nanoparticle containing LSC chimeric protein</article-title><source>Microb. Pathog.</source><volume>134</volume><year>2019</year><object-id pub-id-type="publisher-id">103600</object-id><pub-id pub-id-type="doi">10.1016/j.micpath.2019.103600</pub-id><pub-id pub-id-type="pmid">31202906</pub-id></element-citation></ref><ref id="b0650"><label>130</label><element-citation publication-type="journal" id="h0650"><person-group person-group-type="author"><name name-style="western"><surname>Barel</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Mulard</surname><given-names>L.A.</given-names></name></person-group><article-title>Classical and novel strategies to develop a <italic toggle="yes">Shigella glycoconjugate</italic> vaccine: From concept to efficacy in human</article-title><source>Hum. Vaccin. Immunother.</source><volume>15</volume><year>2019</year><fpage>1338</fpage><lpage>1356</lpage><pub-id pub-id-type="doi">10.1080/21645515.2019.1606972</pub-id><pub-id pub-id-type="pmid">31158047</pub-id><pub-id pub-id-type="pmcid">PMC6663142</pub-id></element-citation></ref><ref id="b0655"><label>131</label><element-citation publication-type="journal" id="h0655"><person-group person-group-type="author"><name name-style="western"><surname>Gilavand</surname><given-names>F.</given-names></name><name name-style="western"><surname>Marzban</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ebrahimipour</surname><given-names>G.</given-names></name><name name-style="western"><surname>Soleimani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Goudarzi</surname><given-names>M.</given-names></name></person-group><article-title>Designation of chitosan nano-vaccine based on MxiH antigen of <italic toggle="yes">Shigella flexneri</italic> with increased immunization capacity</article-title><source>Carbohydr. Polym.</source><volume>232</volume><year>2020</year><object-id pub-id-type="publisher-id">115813</object-id><pub-id pub-id-type="doi">10.1016/j.carbpol.2019.115813</pub-id><pub-id pub-id-type="pmid">31952611</pub-id></element-citation></ref><ref id="b0660"><label>132</label><element-citation publication-type="journal" id="h0660"><person-group person-group-type="author"><name name-style="western"><surname>des Rieux</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fievez</surname><given-names>V.</given-names></name><name name-style="western"><surname>Garinot</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Pr&#233;at</surname><given-names>V.</given-names></name></person-group><article-title>Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach</article-title><source>J. Control. Release</source><volume>116</volume><issue>1</issue><year>2006</year><fpage>1</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2006.08.013</pub-id><pub-id pub-id-type="pmid">17050027</pub-id></element-citation></ref><ref id="b0665"><label>133</label><element-citation publication-type="journal" id="h0665"><person-group person-group-type="author"><name name-style="western"><surname>van der Lubben</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Verhoef</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Borchard</surname><given-names>G.</given-names></name><name name-style="western"><surname>Junginger</surname><given-names>H.E.</given-names></name></person-group><article-title>Chitosan and its derivatives in mucosal drug and vaccine delivery</article-title><source>Eur. J. Pharm. Sci.</source><volume>14</volume><year>2001</year><fpage>201</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/s0928-0987(01)00172-5</pub-id><pub-id pub-id-type="pmid">11576824</pub-id></element-citation></ref><ref id="b0670"><label>134</label><element-citation publication-type="journal" id="h0670"><person-group person-group-type="author"><name name-style="western"><surname>Pastor</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ting</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mart&#237;nez</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Irache</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Gamazo</surname><given-names>C.</given-names></name></person-group><article-title>Intranasal delivery system of bacterial antigen using thermo-sensitive hydrogels based on a Pluronic-Gantrez conjugate</article-title><source>Int. J. Pharm.</source><volume>579</volume><year>2020</year><object-id pub-id-type="publisher-id">119154</object-id><pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119154</pub-id><pub-id pub-id-type="pmid">32081801</pub-id></element-citation></ref><ref id="b0675"><label>135</label><element-citation publication-type="journal" id="h0675"><person-group person-group-type="author"><name name-style="western"><surname>Akbari</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Saadati</surname><given-names>M.</given-names></name><name name-style="western"><surname>Honari</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ghorbani</surname><given-names>H.M.</given-names></name></person-group><article-title>IpaD-loaded <italic toggle="yes">N</italic>-trimethyl chitosan nanoparticles can efficiently protect guinea pigs against <italic toggle="yes">Shigella flexneri</italic></article-title><source>Iran. J. Immunol.</source><volume>16</volume><year>2019</year><fpage>212</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.22034/iji.2019.80272</pub-id><pub-id pub-id-type="pmid">31552830</pub-id></element-citation></ref><ref id="b0680"><label>136</label><element-citation publication-type="journal" id="h0680"><person-group person-group-type="author"><name name-style="western"><surname>Lycke</surname><given-names>N.</given-names></name></person-group><article-title>From toxin to adjuvant: Basic mechanisms for the control of mucosal IgA immunity and tolerance</article-title><source>Immunol. Lett.</source><volume>97</volume><year>2005</year><fpage>193</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2004.12.008</pub-id><pub-id pub-id-type="pmid">15752558</pub-id></element-citation></ref><ref id="b0685"><label>137</label><element-citation publication-type="journal" id="h0685"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name></person-group><article-title>Orthogonal modular biosynthesis of nanoscale conjugate vaccines for vaccination against infection</article-title><source>Nano Res.</source><year>2021</year><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s12274-021-3713-4</pub-id><pub-id pub-id-type="pmcid">PMC8359766</pub-id><pub-id pub-id-type="pmid">34405037</pub-id></element-citation></ref><ref id="b0690"><label>138</label><element-citation publication-type="journal" id="h0690"><person-group person-group-type="author"><name name-style="western"><surname>Barry</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cassels</surname><given-names>F.</given-names></name><name name-style="western"><surname>Riddle</surname><given-names>M.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wierzba</surname><given-names>T.</given-names></name></person-group><article-title>Vaccines against <italic toggle="yes">Shigella</italic> and enterotoxigenic <italic toggle="yes">Escherichia coli</italic>: A summary of the 2018 VASE conference</article-title><source>Vaccine</source><volume>37</volume><year>2019</year><fpage>4768</fpage><lpage>4774</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.02.070</pub-id><pub-id pub-id-type="pmid">31358236</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>